Example Output

• Il Mago di Oz, in vendita all’asta il famoso abito di Judy Garland
• Higher COVID-19 death rates in the southern U.S. due to behavior variations, study finds
• Scientists call for cap on production to end plastic pollution
• Tom Holland and Levon Thurman-Hawke sport 1970’s inspired outfits on set of The Crowded Room
• Msc apre le vendite per l’estate 2023: 22 navi per oltre 140 destinazioni
• El amor de Scarlett Johansson por la moda masculina inspiró un momento de alfombra roja a juego con Colin Jost – Inicio
• Telefilm Canada unveils 15 Micro-Budget Production finallists
• Gene mutations that contribute to head and neck cancer also provide ‘precision’ treatment targets
• Jeff Goldblum Comparte Pensamientos Después De Ver Jurassic World: Dominion (y Ya Tiene Planes De Volver) – Noticias Del Mundo En Español
• Unravelling the origins of the human spine

Parsed Results (var_dump'ed)

object(MagpieRSS)#4 (23) {
  ["parser"]=>
  resource(14) of type (Unknown)
  ["current_item"]=>
  array(0) {
  }
  ["items"]=>
  array(10) {
    [0]=>
    array(11) {
      ["title"]=>
      string(68) "Il Mago di Oz, in vendita all’asta il famoso abito di Judy Garland"
      ["link"]=>
      string(94) "https://coolnspicy.com/shows/il-mago-di-oz-in-vendita-allasta-il-famoso-abito-di-judy-garland/"
      ["dc"]=>
      array(1) {
        ["creator"]=>
        string(12) "Sally Scully"
      }
      ["pubdate"]=>
      string(31) "Fri, 29 Apr 2022 04:28:44 +0000"
      ["category"]=>
      string(45) "ShowsabitoallastafamosoGarlandJudyMagovendita"
      ["guid"]=>
      string(31) "https://coolnspicy.com/?p=24552"
      ["description"]=>
      string(680) "
 
 
 
 Somewhere over the rainbow. Da qualche parte oltre l’arcobaleno. Proprio così recita la colonna sonora del film ‘Il Mago di Oz‘ e proprio lì doveva essersi cacciato per tutti questi anni il celebre abito bianco e celeste di Dorothy Gale alias Judy Garland.   Leggi anche > Disney+, tutte le serie tv in uscita a ... Read more"
      ["content"]=>
      array(1) {
        ["encoded"]=>
        string(4823) "



                


                                


                

Somewhere over the rainbow. Da qualche parte oltre l’arcobaleno. Proprio così recita la colonna sonora del film ‘Il Mago di Oz‘ e proprio lì doveva essersi cacciato per tutti questi anni il celebre abito bianco e celeste di Dorothy Gale alias Judy Garland.
 
Leggi anche > Disney+, tutte le serie tv in uscita a maggio 2022
 


 
Il Mago di Oz, in vendita all’asta il famoso abito di Judy Garland
Dopo oltre 80 anni dall’uscita della pellicola sul grande schermo nel 1939, il vestito che si credeva smarrito per sempre è stato ritrovato e il prossimo mese sarà venduto all’asta. A renderlo noto è il magazine Town&Country che ricostruisce l’avventurosa vicenda di questo costume di scena e del suo fortunoso ritrovamento lo scorso anno.
Come racconta la testata, la storia incomincia nel 1973 quando l’attrice hollywoodiana Mercedes McCambridge decide di donare alla Catholic University of America (CUA) il celebre vestito. L’artista era quasi coetanea di Judy e le due devono essere state presumibilmente amiche, ma non è chiaro come sia entrata in possesso dell’indumento. Tuttavia a partire dal 1980 si perde ogni traccia del prezioso abito, che salta fuori del tutto casualmente solo dopo 40 anni, nel 2021.
«Avevo guardato nei nostri archivi, armadi, ecc. senza alcun risultato» ha spiegato il docente Matt Ripa. «[Io] supponevo che fosse una “leggenda”. Il nostro edificio è in fase di ristrutturazione e aggiornamenti, quindi stavo pulendo il mio ufficio per prepararmi. Ho notato in cima alle cassette postali della facoltà un sacchetto della spazzatura e ho chiesto al mio collega di consegnarmelo. Sul cestino c’era un biglietto che diceva che qualcuno aveva trovato “questo” nel suo ufficio e che doveva averlo spostato quando si era trasferito. Ero curioso di sapere cosa c’era dentro: ho aperto il sacchetto della spazzatura, dentro c’era una scatola da scarpe e all’interno della scatola delle scarpe c’era il vestito! Non potevo crederci».
Presentato alla casa d’aste Bonhams Classic Hollywood: Film and Television sale di Los Angeles per la vendita, l’abito è stato stimato tra gli 800mila dollari e 1,2 milioni di dollari. Secondo Bonhams, il vestito è stato «scelto per una specifica scena dell’amato film, vale a dire quando Dorothy affronta la Strega Malvagia dell’Ovest [interpretata da Margaret Hamilton, ndr] nel Castello delle Streghe».
Quando si terrà l’asta
«Scoprire questo abito storico è stato un momento memorabile per la Catholic University of America e siamo orgogliosi di presentarlo all’asta, in modo che il prossimo collezionista possa possedere un pezzo di storia» ha detto Jacqueline J. Leary-Warsaw, preside della Benjamin T. Rome School of Music, Drama, and Art, in un comunicato stampa. Attualmente l’abito “Dorothy” di Judy Garland è in mostra al Bonhams di New York e dal 20 al 24 maggio sarà visibile al Bonhams di Los Angeles prima che venga messo all’asta il 24 maggio.
Separarsi da questo pezzo di storia del cinema è una sensazione «dolceamara», spiega la professoressa, ma «il ricavato contribuirà a sostenere la formazione delle generazioni future per le carriere professionali nel teatro» a beneficio del Dipartimento Drammatico della CUA. E chissà che proprio il denaro raccolto non contribuisca a finanziare gli studi della futura Judy Garland!
                








                Ultimo aggiornamento: Giovedì 28 Aprile 2022, 22:27


                



                


                  © RIPRODUZIONE RISERVATA            
We  would love to  say thanks to the  writer of this  short article for this  amazing  material



Il Mago di Oz, in vendita all’asta il famoso abito di Judy Garland

"
      }
      ["summary"]=>
      string(680) "
 
 
 
 Somewhere over the rainbow. Da qualche parte oltre l’arcobaleno. Proprio così recita la colonna sonora del film ‘Il Mago di Oz‘ e proprio lì doveva essersi cacciato per tutti questi anni il celebre abito bianco e celeste di Dorothy Gale alias Judy Garland.   Leggi anche > Disney+, tutte le serie tv in uscita a ... Read more"
      ["atom_content"]=>
      string(4823) "



                


                                


                

Somewhere over the rainbow. Da qualche parte oltre l’arcobaleno. Proprio così recita la colonna sonora del film ‘Il Mago di Oz‘ e proprio lì doveva essersi cacciato per tutti questi anni il celebre abito bianco e celeste di Dorothy Gale alias Judy Garland.
 
Leggi anche > Disney+, tutte le serie tv in uscita a maggio 2022
 


 
Il Mago di Oz, in vendita all’asta il famoso abito di Judy Garland
Dopo oltre 80 anni dall’uscita della pellicola sul grande schermo nel 1939, il vestito che si credeva smarrito per sempre è stato ritrovato e il prossimo mese sarà venduto all’asta. A renderlo noto è il magazine Town&Country che ricostruisce l’avventurosa vicenda di questo costume di scena e del suo fortunoso ritrovamento lo scorso anno.
Come racconta la testata, la storia incomincia nel 1973 quando l’attrice hollywoodiana Mercedes McCambridge decide di donare alla Catholic University of America (CUA) il celebre vestito. L’artista era quasi coetanea di Judy e le due devono essere state presumibilmente amiche, ma non è chiaro come sia entrata in possesso dell’indumento. Tuttavia a partire dal 1980 si perde ogni traccia del prezioso abito, che salta fuori del tutto casualmente solo dopo 40 anni, nel 2021.
«Avevo guardato nei nostri archivi, armadi, ecc. senza alcun risultato» ha spiegato il docente Matt Ripa. «[Io] supponevo che fosse una “leggenda”. Il nostro edificio è in fase di ristrutturazione e aggiornamenti, quindi stavo pulendo il mio ufficio per prepararmi. Ho notato in cima alle cassette postali della facoltà un sacchetto della spazzatura e ho chiesto al mio collega di consegnarmelo. Sul cestino c’era un biglietto che diceva che qualcuno aveva trovato “questo” nel suo ufficio e che doveva averlo spostato quando si era trasferito. Ero curioso di sapere cosa c’era dentro: ho aperto il sacchetto della spazzatura, dentro c’era una scatola da scarpe e all’interno della scatola delle scarpe c’era il vestito! Non potevo crederci».
Presentato alla casa d’aste Bonhams Classic Hollywood: Film and Television sale di Los Angeles per la vendita, l’abito è stato stimato tra gli 800mila dollari e 1,2 milioni di dollari. Secondo Bonhams, il vestito è stato «scelto per una specifica scena dell’amato film, vale a dire quando Dorothy affronta la Strega Malvagia dell’Ovest [interpretata da Margaret Hamilton, ndr] nel Castello delle Streghe».
Quando si terrà l’asta
«Scoprire questo abito storico è stato un momento memorabile per la Catholic University of America e siamo orgogliosi di presentarlo all’asta, in modo che il prossimo collezionista possa possedere un pezzo di storia» ha detto Jacqueline J. Leary-Warsaw, preside della Benjamin T. Rome School of Music, Drama, and Art, in un comunicato stampa. Attualmente l’abito “Dorothy” di Judy Garland è in mostra al Bonhams di New York e dal 20 al 24 maggio sarà visibile al Bonhams di Los Angeles prima che venga messo all’asta il 24 maggio.
Separarsi da questo pezzo di storia del cinema è una sensazione «dolceamara», spiega la professoressa, ma «il ricavato contribuirà a sostenere la formazione delle generazioni future per le carriere professionali nel teatro» a beneficio del Dipartimento Drammatico della CUA. E chissà che proprio il denaro raccolto non contribuisca a finanziare gli studi della futura Judy Garland!
                








                Ultimo aggiornamento: Giovedì 28 Aprile 2022, 22:27


                



                


                  © RIPRODUZIONE RISERVATA            
We  would love to  say thanks to the  writer of this  short article for this  amazing  material



Il Mago di Oz, in vendita all’asta il famoso abito di Judy Garland

"
      ["date_timestamp"]=>
      int(1651206524)
    }
    [1]=>
    array(11) {
      ["title"]=>
      string(88) "Higher COVID-19 death rates in the southern U.S. due to behavior variations, study finds"
      ["link"]=>
      string(127) "https://coolnspicy.com/healthandscience/higher-covid-19-death-rates-in-the-southern-u-s-due-to-behavior-variations-study-finds/"
      ["dc"]=>
      array(1) {
        ["creator"]=>
        string(12) "Tony Grantly"
      }
      ["pubdate"]=>
      string(31) "Fri, 29 Apr 2022 04:07:16 +0000"
      ["category"]=>
      string(66) "Health And SciencebehaviorCovid19deathratessouthernStudyvariations"
      ["guid"]=>
      string(31) "https://coolnspicy.com/?p=24547"
      ["description"]=>
      string(772) "Journal Reference: Michael A. Stoto, Samantha Schlageter, John D. Kraemer. COVID-19 mortality in the United States: It’s been two Americas from the start. PLOS ONE, 2022; 17 (4): e0265053 DOI: 10.1371/journal.pone.0265053 The study, by Georgetown University’s School of Nursing & Health Studies researchers, appeared April 28, 2022, in PLOS ONE. Excess mortality, which helps account ... Read more"
      ["content"]=>
      array(1) {
        ["encoded"]=>
        string(4277) "

Journal Reference:

Michael A. Stoto, Samantha Schlageter, John D. Kraemer. COVID-19 mortality in the United States: It’s been two Americas from the start. PLOS ONE, 2022; 17 (4): e0265053 DOI: 10.1371/journal.pone.0265053


The study, by Georgetown University’s School of Nursing & Health Studies researchers, appeared April 28, 2022, in PLOS ONE.
Excess mortality, which helps account for avoidable deaths from a new disease or situation, is defined by the difference between total current deaths and deaths expected based on earlier time period, usually the previous decade or so. The U.S. Centers for Disease Control and Prevention (CDC) calculates these numbers weekly. For this study, the CDC excess mortality data were analyzed for the period between January 3, 2020, to September 26, 2021. For regional comparison purposes, areas of the country were broken down into the Northeast, Midwest, South and West.
“Our goal was to carefully examine regional differences in COVID-19 death rates based on reliable statistical data,” says Michael Stoto, Ph.D., professor of Health Systems Administration and Population Health at the School of Nursing & Health Studies and corresponding author of the study. “Our study is the first to quantify avoidable deaths and confirm that both COVID-19 deaths and avoidable deaths disproportionately occurred in the South.”
The investigators found that regional differences in COVID-19 mortality rates have persisted throughout the pandemic. The southern part of the United States has had higher mortality rates than the rest of the U.S. since the start of summer in 2020. Since October 2020, 48% of COVID-19 deaths were in the South, which makes up 38% of the population, pointing to disproportionate outcomes regionally.
The researchers also determined that between January 2020 and September 2021 there were 895,693 excess deaths associated with COVID-19, which is 26% more than reported by other experts who track disease. Although the official total neared on one million deaths in the U.S due to COVID-19 by late April 2022, based on this undercount the scientists believe that threshold was actually passed at the beginning of 2022.
These estimates of undercounts are important because most studies have looked at excess mortality at the state and county level in the U.S., but because of small population sizes, the studies have not examined patterns over time. Some earlier studies explored the relationship between COVID-19 mortality and age, education, and other factors as well as vaccine uptake, party affiliation, and other factors. But most studies have used reported COVID-19 deaths rather than excess deaths, as compared to what Dr. Stoto and collaborators have done, and may not be as statistically reliable.
“This is one of a series of planned studies to look carefully at the response to COVID-19 in the U.S. and other countries and to learn from the experience in order to strengthen preparedness for future potential outbreaks,” says Stoto. “Our team has also looked at testing and surveillance, and other COVID-19 metrics to understand how communities have come together to effectively deal with the pandemic.”
In addition to Stoto, the other authors from Georgetown include Samantha Schlageter, who conducted this work as an undergraduate in the Health Care Management & Policy program at the School of Nursing & Health Studies (NHS), and John D. Kraemer, an associate professor in Department of Health Systems Administration at NHS.

We would like to  give thanks to the  writer of this  post for this  amazing  web content



Higher COVID-19 death rates in the southern U.S. due to behavior variations, study finds

"
      }
      ["summary"]=>
      string(772) "Journal Reference: Michael A. Stoto, Samantha Schlageter, John D. Kraemer. COVID-19 mortality in the United States: It’s been two Americas from the start. PLOS ONE, 2022; 17 (4): e0265053 DOI: 10.1371/journal.pone.0265053 The study, by Georgetown University’s School of Nursing & Health Studies researchers, appeared April 28, 2022, in PLOS ONE. Excess mortality, which helps account ... Read more"
      ["atom_content"]=>
      string(4277) "

Journal Reference:

Michael A. Stoto, Samantha Schlageter, John D. Kraemer. COVID-19 mortality in the United States: It’s been two Americas from the start. PLOS ONE, 2022; 17 (4): e0265053 DOI: 10.1371/journal.pone.0265053


The study, by Georgetown University’s School of Nursing & Health Studies researchers, appeared April 28, 2022, in PLOS ONE.
Excess mortality, which helps account for avoidable deaths from a new disease or situation, is defined by the difference between total current deaths and deaths expected based on earlier time period, usually the previous decade or so. The U.S. Centers for Disease Control and Prevention (CDC) calculates these numbers weekly. For this study, the CDC excess mortality data were analyzed for the period between January 3, 2020, to September 26, 2021. For regional comparison purposes, areas of the country were broken down into the Northeast, Midwest, South and West.
“Our goal was to carefully examine regional differences in COVID-19 death rates based on reliable statistical data,” says Michael Stoto, Ph.D., professor of Health Systems Administration and Population Health at the School of Nursing & Health Studies and corresponding author of the study. “Our study is the first to quantify avoidable deaths and confirm that both COVID-19 deaths and avoidable deaths disproportionately occurred in the South.”
The investigators found that regional differences in COVID-19 mortality rates have persisted throughout the pandemic. The southern part of the United States has had higher mortality rates than the rest of the U.S. since the start of summer in 2020. Since October 2020, 48% of COVID-19 deaths were in the South, which makes up 38% of the population, pointing to disproportionate outcomes regionally.
The researchers also determined that between January 2020 and September 2021 there were 895,693 excess deaths associated with COVID-19, which is 26% more than reported by other experts who track disease. Although the official total neared on one million deaths in the U.S due to COVID-19 by late April 2022, based on this undercount the scientists believe that threshold was actually passed at the beginning of 2022.
These estimates of undercounts are important because most studies have looked at excess mortality at the state and county level in the U.S., but because of small population sizes, the studies have not examined patterns over time. Some earlier studies explored the relationship between COVID-19 mortality and age, education, and other factors as well as vaccine uptake, party affiliation, and other factors. But most studies have used reported COVID-19 deaths rather than excess deaths, as compared to what Dr. Stoto and collaborators have done, and may not be as statistically reliable.
“This is one of a series of planned studies to look carefully at the response to COVID-19 in the U.S. and other countries and to learn from the experience in order to strengthen preparedness for future potential outbreaks,” says Stoto. “Our team has also looked at testing and surveillance, and other COVID-19 metrics to understand how communities have come together to effectively deal with the pandemic.”
In addition to Stoto, the other authors from Georgetown include Samantha Schlageter, who conducted this work as an undergraduate in the Health Care Management & Policy program at the School of Nursing & Health Studies (NHS), and John D. Kraemer, an associate professor in Department of Health Systems Administration at NHS.

We would like to  give thanks to the  writer of this  post for this  amazing  web content



Higher COVID-19 death rates in the southern U.S. due to behavior variations, study finds

"
      ["date_timestamp"]=>
      int(1651205236)
    }
    [2]=>
    array(11) {
      ["title"]=>
      string(62) "Scientists call for cap on production to end plastic pollution"
      ["link"]=>
      string(103) "https://coolnspicy.com/healthandscience/scientists-call-for-cap-on-production-to-end-plastic-pollution/"
      ["dc"]=>
      array(1) {
        ["creator"]=>
        string(12) "Tony Grantly"
      }
      ["pubdate"]=>
      string(31) "Fri, 29 Apr 2022 02:50:15 +0000"
      ["category"]=>
      string(57) "Health And Sciencecapplasticpollutionproductionscientists"
      ["guid"]=>
      string(31) "https://coolnspicy.com/?p=24542"
      ["description"]=>
      string(696) "Journal Reference: Melanie Bergmann, Bethanie Carney Almroth, Susanne M. Brander, Tridibesh Dey, Dannielle S. Green, Sedat Gundogdu, Anja Krieger, Martin Wagner, Tony R. Walker. A global plastic treaty must cap production. Science, 2022; 376 (6592): 469 DOI: 10.1126/science.abq0082 Now, after the United Nations’ historic decision to adopt a global treaty to end plastic pollution earlier ... Read more"
      ["content"]=>
      array(1) {
        ["encoded"]=>
        string(4173) "

Journal Reference:

Melanie Bergmann, Bethanie Carney Almroth, Susanne M. Brander, Tridibesh Dey, Dannielle S. Green, Sedat Gundogdu, Anja Krieger, Martin Wagner, Tony R. Walker. A global plastic treaty must cap production. Science, 2022; 376 (6592): 469 DOI: 10.1126/science.abq0082


Now, after the United Nations’ historic decision to adopt a global treaty to end plastic pollution earlier this year, governmental negotiations on the agreement are set to begin on May 30th. These will foster intense debates on what kind of measures will be needed to end the pollution of the air, soils, rivers and oceans with plastic debris and microplastics.
In a letter to the journal Science, an international group of scientists and experts now argue for tackling the issue right at the source, by regulating, capping, and in the long term phasing out the production of new plastics.
Recycling not enough
“Even if we recycled better and tried to manage the waste as much as we can, we would still release more than 17 million tons of plastic per year into nature,” says Melanie Bergmann of the German Alfred-Wegener-Institute, the initiator of the letter. “If production just keeps growing and growing, we will be faced with a truly Sisyphean task,” she adds.
Research published in Science in 2020 shows that plastic emissions can only be cut by 79 per cent over the next 20 years if all solutions available today are implemented, including replacing some plastics with other materials, and improved recycling and waste management.
“The exponentially growing production is really the root cause of the problem, and the amounts of plastics we have produced thus far have already exceeded planetary boundaries,” says Bethanie Carney Almroth of the University of Gothenburg, Sweden. “If we don’t tackle that, all other measures will fail to achieve the goal of substantially reducing the release of plastic into the environment,” she said.
Phasing out new plastics important
Phasing out the production of new plastics from fresh feedstocks should be part of a systemic solution to end plastic pollution, the experts from Canada, Germany, India, Norway, Sweden, Turkey, the UK and the U.S. argue. This approach is supported by the best science available today and in line with what political and legal experts proposed in Science last year.
Along with measures to address the consumption and demand side of the problem — such as taxes — a comprehensive approach must also cover the supply side, meaning the actual amount of plastics produced and put on the market.
Gradually cutting the production of new plastics will come with many societal, environmental and economic benefits, the scientists say.
Sedat Gündo?du of the Cukurova University, Turkey, says “The massive production also feeds the plastic waste transfer from the Global North to the South. A production cap will facilitate getting rid of non-essential applications and reduce plastic waste exports.”
“We gain a lot of benefits from plastics but reducing production will increase the value of plastics, boost other measures to curb plastic pollution, help tackle climate change and promote our transition to a circular and sustainable economy,” adds Martin Wagner, an ecotoxicologist at the Norwegian University of Science and Technology.

We  wish to  say thanks to the  writer of this article for this  amazing  material



Scientists call for cap on production to end plastic pollution

"
      }
      ["summary"]=>
      string(696) "Journal Reference: Melanie Bergmann, Bethanie Carney Almroth, Susanne M. Brander, Tridibesh Dey, Dannielle S. Green, Sedat Gundogdu, Anja Krieger, Martin Wagner, Tony R. Walker. A global plastic treaty must cap production. Science, 2022; 376 (6592): 469 DOI: 10.1126/science.abq0082 Now, after the United Nations’ historic decision to adopt a global treaty to end plastic pollution earlier ... Read more"
      ["atom_content"]=>
      string(4173) "

Journal Reference:

Melanie Bergmann, Bethanie Carney Almroth, Susanne M. Brander, Tridibesh Dey, Dannielle S. Green, Sedat Gundogdu, Anja Krieger, Martin Wagner, Tony R. Walker. A global plastic treaty must cap production. Science, 2022; 376 (6592): 469 DOI: 10.1126/science.abq0082


Now, after the United Nations’ historic decision to adopt a global treaty to end plastic pollution earlier this year, governmental negotiations on the agreement are set to begin on May 30th. These will foster intense debates on what kind of measures will be needed to end the pollution of the air, soils, rivers and oceans with plastic debris and microplastics.
In a letter to the journal Science, an international group of scientists and experts now argue for tackling the issue right at the source, by regulating, capping, and in the long term phasing out the production of new plastics.
Recycling not enough
“Even if we recycled better and tried to manage the waste as much as we can, we would still release more than 17 million tons of plastic per year into nature,” says Melanie Bergmann of the German Alfred-Wegener-Institute, the initiator of the letter. “If production just keeps growing and growing, we will be faced with a truly Sisyphean task,” she adds.
Research published in Science in 2020 shows that plastic emissions can only be cut by 79 per cent over the next 20 years if all solutions available today are implemented, including replacing some plastics with other materials, and improved recycling and waste management.
“The exponentially growing production is really the root cause of the problem, and the amounts of plastics we have produced thus far have already exceeded planetary boundaries,” says Bethanie Carney Almroth of the University of Gothenburg, Sweden. “If we don’t tackle that, all other measures will fail to achieve the goal of substantially reducing the release of plastic into the environment,” she said.
Phasing out new plastics important
Phasing out the production of new plastics from fresh feedstocks should be part of a systemic solution to end plastic pollution, the experts from Canada, Germany, India, Norway, Sweden, Turkey, the UK and the U.S. argue. This approach is supported by the best science available today and in line with what political and legal experts proposed in Science last year.
Along with measures to address the consumption and demand side of the problem — such as taxes — a comprehensive approach must also cover the supply side, meaning the actual amount of plastics produced and put on the market.
Gradually cutting the production of new plastics will come with many societal, environmental and economic benefits, the scientists say.
Sedat Gündo?du of the Cukurova University, Turkey, says “The massive production also feeds the plastic waste transfer from the Global North to the South. A production cap will facilitate getting rid of non-essential applications and reduce plastic waste exports.”
“We gain a lot of benefits from plastics but reducing production will increase the value of plastics, boost other measures to curb plastic pollution, help tackle climate change and promote our transition to a circular and sustainable economy,” adds Martin Wagner, an ecotoxicologist at the Norwegian University of Science and Technology.

We  wish to  say thanks to the  writer of this article for this  amazing  material



Scientists call for cap on production to end plastic pollution

"
      ["date_timestamp"]=>
      int(1651200615)
    }
    [3]=>
    array(11) {
      ["title"]=>
      string(95) "Tom Holland and Levon Thurman-Hawke sport 1970’s inspired outfits on set of The Crowded Room"
      ["link"]=>
      string(131) "https://coolnspicy.com/trending-people/tom-holland-and-levon-thurman-hawke-sport-1970s-inspired-outfits-on-set-of-the-crowded-room/"
      ["dc"]=>
      array(1) {
        ["creator"]=>
        string(15) "Pauline Moonlky"
      }
      ["pubdate"]=>
      string(31) "Fri, 29 Apr 2022 02:31:58 +0000"
      ["category"]=>
      string(80) "Trending People1970sandLevonCrowdedHollandInspiredoutfitsSetSportThurmanHawkeTom"
      ["guid"]=>
      string(31) "https://coolnspicy.com/?p=24536"
      ["description"]=>
      string(756) "Tom Holland and Levon Thurman-Hawke were spotted on the set of their upcoming anthology series, The Crowded Room, on Thursday in New York City. Both actors sported 1970’s style looks for their roles, with the Spider-Man star, 25, rocking a green and blue jacket, navy pants, and Clarks Wallabees brown suede boots. Meanwhile Levon, 20 – ... Read more"
      ["content"]=>
      array(1) {
        ["encoded"]=>
        string(10689) "

Tom Holland and Levon Thurman-Hawke were spotted on the set of their upcoming anthology series, The Crowded Room, on Thursday in New York City.
Both actors sported 1970’s style looks for their roles, with the Spider-Man star, 25, rocking a green and blue jacket, navy pants, and Clarks Wallabees brown suede boots.
Meanwhile Levon, 20 – who is the son of A-list actors Uma Thurman, 51, and Ethan Hawke, 51 – wore an all-denim look, featuring a light jean jacket and darker pants.


  
  
 70’s style: Tom Holland, 25, was spotted rocking a 1970’s inspired outfit on the set of his upcoming anthology series, The Crowded Room, on Thursday in New York City

Holland – who also serves as executive producer of the series – sported a striped shirt underneath his jacket and carried a magazine in his hand. 
The Uncharted actor’s brown locks were grown out to a longer length, and styled into loose curls.
Levon’s look was finalized with a pair of checkered Vans. His blonde hair was parted in the middle and worn in a straight style. 


  
  
Co-star: Holland’s co-star Levon Thurman-Hawke, 20, was also on set and sported an all-denim look, featuring a light jean jacket and darker pants



  
  
Famous parents: Levon is the son of A-list actors Uma Thurman, 51, and Ethan Hawke, 51, who split in 2003 and finalized their divorce in 2005; Pictured in 2002 

Also on set was Sam Vartholomeos, 27, who looked cool in a burgundy windbreaker, yellow T-shirt, blue jeans and brown sneakers. 
The three actors were seen standing by an ice-cream truck, with Levon holding a pair of silver handcuffs in his hands.
Filming of the Apple TV+ series, which is based partly on the true story of Billy Milligan, a.k.a. The Campus Rapist, had begun on March 31, 2022. 


  
  
Vintage feel: The Spider-Man star looked cool in a green and blue jacket, navy pants, and Clarks Wallabees brown suede boots



  
  
The trio: Also on set was Sam Vartholomeos, 27, who looked cool in a burgundy windbreaker, yellow T-shirt, blue jeans and brown sneakers

The Crowded Room ‘is an anthology series that will explore inspirational stories of those who have struggled with mental illness and learned to live successfully with it,’ according to Deadline. 
Season one, which will be 10 episodes, is based on the life of writer and producer Akiva Goldsman as well as parts of Daniel Keyes’s nonfiction novel, The Minds of Billy Milligan.
In the late 1970s, Milligan was put on trial for multiple counts of robbery, kidnapping, and rape, but he avoided going to prison by pleading insanity.


  
  
Mischievous: The three actors were seen standing by an ice-cream truck, with Levon holding a pair of silver handcuffs in his hands

After being examined by medical professionals, it was concluded that he had more than 20 different personalities.
Milligan was the first person to be acquitted of a major crime due to his dissociative identity disorder. 
Holland is set to portray Danny Sullivan, a character based on Milligan.


  
  
True crime: The Crowded Room is an Apple TV+ series which is based partly on the true story of Billy Milligan, a.k.a. The Campus Rapist

Multiple Personality Disorder is a now defunct diagnosis currently known as dissociative identity disorder.
The cast also includes Emmy Rossum, who will play Danny’s mother Candy, and Amanda Seyfried, who has been cast as ‘a clinical psychologist faced with the most challenging case of her career.’ 
It is unknown when the true-crime show will be released, but it likely won’t be until 2023 at the earliest. 


  
  
Intriguing role: Holland is set to portray Danny Sullivan, a character based on Milligan, who was the first person to be acquitted of a major crime due to his dissociative identity disorder


We  would love to  give thanks to the author of this  short article for this  remarkable  web content



Tom Holland and Levon Thurman-Hawke sport 1970’s inspired outfits on set of The Crowded Room

"
      }
      ["summary"]=>
      string(756) "Tom Holland and Levon Thurman-Hawke were spotted on the set of their upcoming anthology series, The Crowded Room, on Thursday in New York City. Both actors sported 1970’s style looks for their roles, with the Spider-Man star, 25, rocking a green and blue jacket, navy pants, and Clarks Wallabees brown suede boots. Meanwhile Levon, 20 – ... Read more"
      ["atom_content"]=>
      string(10689) "

Tom Holland and Levon Thurman-Hawke were spotted on the set of their upcoming anthology series, The Crowded Room, on Thursday in New York City.
Both actors sported 1970’s style looks for their roles, with the Spider-Man star, 25, rocking a green and blue jacket, navy pants, and Clarks Wallabees brown suede boots.
Meanwhile Levon, 20 – who is the son of A-list actors Uma Thurman, 51, and Ethan Hawke, 51 – wore an all-denim look, featuring a light jean jacket and darker pants.


  
  
 70’s style: Tom Holland, 25, was spotted rocking a 1970’s inspired outfit on the set of his upcoming anthology series, The Crowded Room, on Thursday in New York City

Holland – who also serves as executive producer of the series – sported a striped shirt underneath his jacket and carried a magazine in his hand. 
The Uncharted actor’s brown locks were grown out to a longer length, and styled into loose curls.
Levon’s look was finalized with a pair of checkered Vans. His blonde hair was parted in the middle and worn in a straight style. 


  
  
Co-star: Holland’s co-star Levon Thurman-Hawke, 20, was also on set and sported an all-denim look, featuring a light jean jacket and darker pants



  
  
Famous parents: Levon is the son of A-list actors Uma Thurman, 51, and Ethan Hawke, 51, who split in 2003 and finalized their divorce in 2005; Pictured in 2002 

Also on set was Sam Vartholomeos, 27, who looked cool in a burgundy windbreaker, yellow T-shirt, blue jeans and brown sneakers. 
The three actors were seen standing by an ice-cream truck, with Levon holding a pair of silver handcuffs in his hands.
Filming of the Apple TV+ series, which is based partly on the true story of Billy Milligan, a.k.a. The Campus Rapist, had begun on March 31, 2022. 


  
  
Vintage feel: The Spider-Man star looked cool in a green and blue jacket, navy pants, and Clarks Wallabees brown suede boots



  
  
The trio: Also on set was Sam Vartholomeos, 27, who looked cool in a burgundy windbreaker, yellow T-shirt, blue jeans and brown sneakers

The Crowded Room ‘is an anthology series that will explore inspirational stories of those who have struggled with mental illness and learned to live successfully with it,’ according to Deadline. 
Season one, which will be 10 episodes, is based on the life of writer and producer Akiva Goldsman as well as parts of Daniel Keyes’s nonfiction novel, The Minds of Billy Milligan.
In the late 1970s, Milligan was put on trial for multiple counts of robbery, kidnapping, and rape, but he avoided going to prison by pleading insanity.


  
  
Mischievous: The three actors were seen standing by an ice-cream truck, with Levon holding a pair of silver handcuffs in his hands

After being examined by medical professionals, it was concluded that he had more than 20 different personalities.
Milligan was the first person to be acquitted of a major crime due to his dissociative identity disorder. 
Holland is set to portray Danny Sullivan, a character based on Milligan.


  
  
True crime: The Crowded Room is an Apple TV+ series which is based partly on the true story of Billy Milligan, a.k.a. The Campus Rapist

Multiple Personality Disorder is a now defunct diagnosis currently known as dissociative identity disorder.
The cast also includes Emmy Rossum, who will play Danny’s mother Candy, and Amanda Seyfried, who has been cast as ‘a clinical psychologist faced with the most challenging case of her career.’ 
It is unknown when the true-crime show will be released, but it likely won’t be until 2023 at the earliest. 


  
  
Intriguing role: Holland is set to portray Danny Sullivan, a character based on Milligan, who was the first person to be acquitted of a major crime due to his dissociative identity disorder


We  would love to  give thanks to the author of this  short article for this  remarkable  web content



Tom Holland and Levon Thurman-Hawke sport 1970’s inspired outfits on set of The Crowded Room

"
      ["date_timestamp"]=>
      int(1651199518)
    }
    [4]=>
    array(11) {
      ["title"]=>
      string(75) "Msc apre le vendite per l’estate 2023: 22 navi per oltre 140 destinazioni"
      ["link"]=>
      string(104) "https://coolnspicy.com/magazine/msc-apre-le-vendite-per-lestate-2023-22-navi-per-oltre-140-destinazioni/"
      ["dc"]=>
      array(1) {
        ["creator"]=>
        string(15) "Pauline Moonlky"
      }
      ["pubdate"]=>
      string(31) "Fri, 29 Apr 2022 02:15:17 +0000"
      ["category"]=>
      string(50) "MagazineapredestinazionilestateMscnavioltrevendite"
      ["guid"]=>
      string(31) "https://coolnspicy.com/?p=24530"
      ["description"]=>
      string(681) "La World Europa Ventidue navi attive per 140 destinazioni in tutto il mondo, che toccheranno una quarantina di Paesi differenti. Msc Crociere apre le vendite per l’estate 2023 con itinerari che vanno dalle mini-crociere ai viaggi di 21 notti. Tra le novità, spicca la World Europa, prima nave della flotta Msc alimentata a Gnl, che farà ... Read more"
      ["content"]=>
      array(1) {
        ["encoded"]=>
        string(10588) "



La World Europa

Ventidue navi attive per 140 destinazioni in tutto il mondo, che toccheranno una quarantina di Paesi differenti. Msc Crociere apre le vendite per l’estate 2023 con itinerari che vanno dalle mini-crociere ai viaggi di 21 notti. Tra le novità, spicca la World Europa, prima nave della flotta Msc alimentata a Gnl, che farà il proprio debutto a fine 2022 e, dopo aver trascorso la stagione invernale negli Emirati Arabi, passerà la propria prima stagione estiva nel Mediterraneo. Gli itinerari di sette notti saranno caratterizzati dalle destinazioni più suggestive del mare Nostrum, con Genova, Napoli e Messina in Italia, La Valletta a Malta, Barcellona in Spagna e Marsiglia in Francia.
L’altra new entry Seascape offrirà invece crociere alternate di sette notti nei Caraibi con partenza da Miami in Florida (Usa) e ogni itinerario includerà una tappa a Ocean Cay Msc Marine Reserve, l’isola privata della compagnia alle Bahamas, così come altre tappe in destinazioni spettacolari, oltre che alle stesse Bahamas, anche a Puerto Rico, Repubblica Dominicana, Messico, isole Cayman e Giamaica.
“Saranno ben 22 le navi della flotta impegnate per il prossima anno, poiché oltre all’arrivo della World Europa e della Seascape previsto per la fine del 2022, nel 2023 arriverà anche l’Euribia – spiega il managing director di Msc Crociere, Leonardo Massa -. Il Mediterraneo si conferma quindi nostra meta protagonista indiscussa anche nella programmazione estiva del 2023, con ben 14 porti di imbarco solo in Italia”.
Panoramica del programma per l’estate 2023:
 Mediterraneo occidentale

Msc Seashore in partenza da Genova (Italia) il sabato farà tappa verso destinazioni come Civitavecchia (Roma) e Palermo (Italia), Ibiza e Valencia (Spagna) e Marsiglia (Francia)
Msc Seaview da Genova partirà il lunedì per fare tappa a La Spezia e Civitavecchia, Cannes (Francia) e Palma di Maiorca e Barcellona (Spagna). L’itinerario perfetto per gli amanti del sole
Msc Opera partirà da Genova (Italia) la domenica e farà scalo verso destinazioni come Marsiglia (Francia), Barcellona (Spagna), La Goulette (Tunisia), Palermo (Sicilia) e Napoli (Italia)
Msc Orchestra a partire da giugno salperà per crociere di dieci notti in partenza da Genova (Italia) verso destinazioni come Marsiglia (Francia), Malaga, Cadice per Siviglia (Spagna), Lisbona (Portogallo) Alicante/Costa Blanca e Minorca (Spagna), e Olbia (Italia)
Msc World Europa offrirà ai propri ospiti le destinazioni più gettonate del Mediterraneo occidentale: farà homeport a Genova (Italia) da dove partirà la domenica verso destinazioni come Napoli e Messina (Italia), La Valletta (Malta), Barcellona (Spagna) e Marsiglia (Francia)

Mediterraneo orientale:

Msc Divina salperà da Civitavecchia per Roma (Italia) il venerdì e farà scalo verso destinazioni come Siracusa, Taranto, le spiagge mozzafiato in Puglia (Italia) e Santorini e Mykonos (Grecia)
Msc Lirica da Venezia il lunedì e da Bari (Italia) la domenica farà scalo nelle isole greche di Cefalonia/Argostoli, Santorini e Creta
Msc Sinfonia in partenza la domenica da Venezia farà scalo verso destinazioni come Brindisi (Italia), l’isola greca di Mykonos e la destinazione continentale greca del Pireo per Atene, così come Spalato o Zara (Croazia)
Msc Armonia farà homeport a Venezia da dove il sabato partirà verso destinazioni come Kotor (Montenegro), le famose isole greche di Mykonos e Santorini (Grecia) e Bari (Italia)
Msc Musica dal Pireo/Atene (Grecia) la domenica farà scalo verso destinazioni come Santorini (Grecia), Kusadasi (Turchia), Haifa (Israele), le isole di Limassol (Cipro) e Mykonos (Grecia)
Msc Splendida da Trieste/Venezia (Italia) il sabato farà scalo verso destinazioni come Ancona (Italia), la pittoresca città di Dubrovnik (Croazia), Bari (Italia), Corfù (Grecia) e Kotor (Montenegro)

Nord Europa:

Msc Euribia eseguirà spettacolari itinerari di sette notti di navigazione per i fiordi norvegesi con partenze settimanali da Kiel (Germania) con scali tra cui Copenaghen (Danimarca); Hellesylt (Norvegia) per il Geirangerfjord; così come Alesund e Flaam, sempre in Norvegia
Msc Fantasia da Kiel (Germania) offrirà due itinerari alternativi di lunghezza compresa tra sette e 11 notti verso i fiordi norvegesi o le capitali baltiche
Msc Grandiosa da Southampton (Regno Unito) offrirà itinerari tra sette e 15 notti nei fiordi norvegesi, Svezia e Danimarca, la costa atlantica dell’Europa e crociere più lunghe alle isole Canarie (Spagna) e nel Mediterraneo, oltre ad alcune brevi pause di tre e quattro notti
Msc Poesia da Warnemunde/Berlino (Germania) e Copenaghen (Danimarca) offrirà itinerari di lunghezza compresa tra sette e 21 notti verso le capitali baltiche e quattro fiordi norvegesi. Le crociere più lunghe includono una crociera epica con tappe in diverse destinazioni tra Islanda e Groenlandia
Msc Preziosa partirà da Amburgo (Germania) con offrirà itinerari da nove a 15 notti a Capo Nord e Spitsbergen in Norvegia o crociere in Islanda con tappe a Reykjavik Isafjordur e Akureyri e le isole Orkney e Shetland nel Regno Unito. Mentre le crociere in Irlanda includeranno scali a Cork e Dublino, Belfast, Glasgow e Liverpool saranno le tappe in Regno Unito. A partire da settembre 2023, la Preziosa offrirà crociere di sette notti con tappe in cinque delle città più cool d’Europa: Amburgo (Germania) la domenica, Zeebrugge per Bruges e Bruxelles (Belgio), Rotterdam/Amsterdam (Paesi Bassi), Le Havre per Parigi (Francia) e Southampton per Londra (Regno Unito) il venerdì. Con soggiorni prolungati in porto fino a 12 ore, gli ospiti potranno sfruttare al massimo il proprio tempo a terra

Crociere lunghe e mini-crociere:

Msc Divina, da Genova (Italia) e Barcellona (Spagna) offrirà crociere di 11 notti verso le isole Canarie, Marocco e Madeira in ottobre e novembre
Msc Poesia dal 25 settembre al 19 novembre 2023, offrirà viaggi di 11 notti con partenza da Genova (Italia) verso Grecia e Turchia. I punti salienti includono Kusadasi/Efeso e una visita di un giorno intero a Istanbul (Turchia), Pireo/Atene (Grecia), Palermo/Monreale e Civitavecchia/Roma (Italia)
Msc Sinfonia nell’ottobre 2023 offrirà crociere di 11 notti da Genova (Italia) a Civitavecchia/Roma, Messina/Taormina/Vulcano Etna (Italia), Rodi/Lindos; Limassol (Cipro) e Heraklion/Crete (Grecia) e Haifa (Israele)
Tante le mini crociere da tre a cinque notti da poter scegliere sia nella primavera che nell’autunno 2023 per scoprire le iconiche città che si affacciano sul Mediterraneo a bordo di Msc Orchestra in maggio e giugno e Msc Euribia e Msc Seaview in autunno. Anche la nuova ammiraglia Msc World Europa proporrà nell’aprile 2023 un breve tour di quattro notti che partirà da Genova e toccherà i porti di Barcellona e Marsiglia.

Nord America e Caraibi:

Msc Meraviglia da aprile 2023 navigherà tutto l’anno da New York offrendo una grande varietà di itinerari che andranno da sei a 11 notti di lunghezza, tra cui:

Itinerari caraibici di sette o otto notti, con scali a Nassau e Ocean Cay Msc Marine Reserve – la bellissima isola privata alle Bahamas
Itinerari alle Bermuda della durata di sei notti con tre giorni di attracco a King’s Wharf e diversi giorni di relax in mare
Itinerari del Nord di dieci o 11 notti, con scali a Boston, Massachusetts; Portland, Maine (Usa) e Charlottetown, Prince Edward Island; Halifax e Sydney, Nova Scotia; e Saint Johns, Newfoundland (Canada). Gli itinerari di 11 notti includono uno scalo aggiuntivo a Newport, Rhode Island (Usa)




Msc Seascape offrirà due diversi itinerari di sette notti da Miami, Florida:


Caraibi orientali: tappa a Ocean Cay Msc Marine Reserve e Nassau (Bahamas), San Juan (Porto Rico) e Puerto Plata (Repubblica Dominicana)
Caraibi occidentali: con scalo a Ocean Cay Msc Marine Reserve (Bahamas), Cozumel (Messico), George Town (Isole Cayman) e Ocho Rios (Giamaica)


Msc Seaside farà homeport a Orlando, Florida da Port Canaveral, il secondo homeport di Msc in Florida, offrendo:

Crociere di tre e quattro notti alla riserva marina Ocean Cay Msc (Bahamas)
Crociere di sette notti a Cozumel e Costa Maya (Messico), Belize, e Ocean Cay Msc Marine Reserve (Bahamas)


Msc Magnifica da Miami, Florida con nuove crociere brevi di tre o quattro notti il venerdì o il lunedì verso Key West in Florida, Nassau e Ocean Cay Msc Marine Reserve (Bahamas).


We  would love to  give thanks to the author of this article for this awesome  material



Msc apre le vendite per l’estate 2023: 22 navi per oltre 140 destinazioni

"
      }
      ["summary"]=>
      string(681) "La World Europa Ventidue navi attive per 140 destinazioni in tutto il mondo, che toccheranno una quarantina di Paesi differenti. Msc Crociere apre le vendite per l’estate 2023 con itinerari che vanno dalle mini-crociere ai viaggi di 21 notti. Tra le novità, spicca la World Europa, prima nave della flotta Msc alimentata a Gnl, che farà ... Read more"
      ["atom_content"]=>
      string(10588) "



La World Europa

Ventidue navi attive per 140 destinazioni in tutto il mondo, che toccheranno una quarantina di Paesi differenti. Msc Crociere apre le vendite per l’estate 2023 con itinerari che vanno dalle mini-crociere ai viaggi di 21 notti. Tra le novità, spicca la World Europa, prima nave della flotta Msc alimentata a Gnl, che farà il proprio debutto a fine 2022 e, dopo aver trascorso la stagione invernale negli Emirati Arabi, passerà la propria prima stagione estiva nel Mediterraneo. Gli itinerari di sette notti saranno caratterizzati dalle destinazioni più suggestive del mare Nostrum, con Genova, Napoli e Messina in Italia, La Valletta a Malta, Barcellona in Spagna e Marsiglia in Francia.
L’altra new entry Seascape offrirà invece crociere alternate di sette notti nei Caraibi con partenza da Miami in Florida (Usa) e ogni itinerario includerà una tappa a Ocean Cay Msc Marine Reserve, l’isola privata della compagnia alle Bahamas, così come altre tappe in destinazioni spettacolari, oltre che alle stesse Bahamas, anche a Puerto Rico, Repubblica Dominicana, Messico, isole Cayman e Giamaica.
“Saranno ben 22 le navi della flotta impegnate per il prossima anno, poiché oltre all’arrivo della World Europa e della Seascape previsto per la fine del 2022, nel 2023 arriverà anche l’Euribia – spiega il managing director di Msc Crociere, Leonardo Massa -. Il Mediterraneo si conferma quindi nostra meta protagonista indiscussa anche nella programmazione estiva del 2023, con ben 14 porti di imbarco solo in Italia”.
Panoramica del programma per l’estate 2023:
 Mediterraneo occidentale

Msc Seashore in partenza da Genova (Italia) il sabato farà tappa verso destinazioni come Civitavecchia (Roma) e Palermo (Italia), Ibiza e Valencia (Spagna) e Marsiglia (Francia)
Msc Seaview da Genova partirà il lunedì per fare tappa a La Spezia e Civitavecchia, Cannes (Francia) e Palma di Maiorca e Barcellona (Spagna). L’itinerario perfetto per gli amanti del sole
Msc Opera partirà da Genova (Italia) la domenica e farà scalo verso destinazioni come Marsiglia (Francia), Barcellona (Spagna), La Goulette (Tunisia), Palermo (Sicilia) e Napoli (Italia)
Msc Orchestra a partire da giugno salperà per crociere di dieci notti in partenza da Genova (Italia) verso destinazioni come Marsiglia (Francia), Malaga, Cadice per Siviglia (Spagna), Lisbona (Portogallo) Alicante/Costa Blanca e Minorca (Spagna), e Olbia (Italia)
Msc World Europa offrirà ai propri ospiti le destinazioni più gettonate del Mediterraneo occidentale: farà homeport a Genova (Italia) da dove partirà la domenica verso destinazioni come Napoli e Messina (Italia), La Valletta (Malta), Barcellona (Spagna) e Marsiglia (Francia)

Mediterraneo orientale:

Msc Divina salperà da Civitavecchia per Roma (Italia) il venerdì e farà scalo verso destinazioni come Siracusa, Taranto, le spiagge mozzafiato in Puglia (Italia) e Santorini e Mykonos (Grecia)
Msc Lirica da Venezia il lunedì e da Bari (Italia) la domenica farà scalo nelle isole greche di Cefalonia/Argostoli, Santorini e Creta
Msc Sinfonia in partenza la domenica da Venezia farà scalo verso destinazioni come Brindisi (Italia), l’isola greca di Mykonos e la destinazione continentale greca del Pireo per Atene, così come Spalato o Zara (Croazia)
Msc Armonia farà homeport a Venezia da dove il sabato partirà verso destinazioni come Kotor (Montenegro), le famose isole greche di Mykonos e Santorini (Grecia) e Bari (Italia)
Msc Musica dal Pireo/Atene (Grecia) la domenica farà scalo verso destinazioni come Santorini (Grecia), Kusadasi (Turchia), Haifa (Israele), le isole di Limassol (Cipro) e Mykonos (Grecia)
Msc Splendida da Trieste/Venezia (Italia) il sabato farà scalo verso destinazioni come Ancona (Italia), la pittoresca città di Dubrovnik (Croazia), Bari (Italia), Corfù (Grecia) e Kotor (Montenegro)

Nord Europa:

Msc Euribia eseguirà spettacolari itinerari di sette notti di navigazione per i fiordi norvegesi con partenze settimanali da Kiel (Germania) con scali tra cui Copenaghen (Danimarca); Hellesylt (Norvegia) per il Geirangerfjord; così come Alesund e Flaam, sempre in Norvegia
Msc Fantasia da Kiel (Germania) offrirà due itinerari alternativi di lunghezza compresa tra sette e 11 notti verso i fiordi norvegesi o le capitali baltiche
Msc Grandiosa da Southampton (Regno Unito) offrirà itinerari tra sette e 15 notti nei fiordi norvegesi, Svezia e Danimarca, la costa atlantica dell’Europa e crociere più lunghe alle isole Canarie (Spagna) e nel Mediterraneo, oltre ad alcune brevi pause di tre e quattro notti
Msc Poesia da Warnemunde/Berlino (Germania) e Copenaghen (Danimarca) offrirà itinerari di lunghezza compresa tra sette e 21 notti verso le capitali baltiche e quattro fiordi norvegesi. Le crociere più lunghe includono una crociera epica con tappe in diverse destinazioni tra Islanda e Groenlandia
Msc Preziosa partirà da Amburgo (Germania) con offrirà itinerari da nove a 15 notti a Capo Nord e Spitsbergen in Norvegia o crociere in Islanda con tappe a Reykjavik Isafjordur e Akureyri e le isole Orkney e Shetland nel Regno Unito. Mentre le crociere in Irlanda includeranno scali a Cork e Dublino, Belfast, Glasgow e Liverpool saranno le tappe in Regno Unito. A partire da settembre 2023, la Preziosa offrirà crociere di sette notti con tappe in cinque delle città più cool d’Europa: Amburgo (Germania) la domenica, Zeebrugge per Bruges e Bruxelles (Belgio), Rotterdam/Amsterdam (Paesi Bassi), Le Havre per Parigi (Francia) e Southampton per Londra (Regno Unito) il venerdì. Con soggiorni prolungati in porto fino a 12 ore, gli ospiti potranno sfruttare al massimo il proprio tempo a terra

Crociere lunghe e mini-crociere:

Msc Divina, da Genova (Italia) e Barcellona (Spagna) offrirà crociere di 11 notti verso le isole Canarie, Marocco e Madeira in ottobre e novembre
Msc Poesia dal 25 settembre al 19 novembre 2023, offrirà viaggi di 11 notti con partenza da Genova (Italia) verso Grecia e Turchia. I punti salienti includono Kusadasi/Efeso e una visita di un giorno intero a Istanbul (Turchia), Pireo/Atene (Grecia), Palermo/Monreale e Civitavecchia/Roma (Italia)
Msc Sinfonia nell’ottobre 2023 offrirà crociere di 11 notti da Genova (Italia) a Civitavecchia/Roma, Messina/Taormina/Vulcano Etna (Italia), Rodi/Lindos; Limassol (Cipro) e Heraklion/Crete (Grecia) e Haifa (Israele)
Tante le mini crociere da tre a cinque notti da poter scegliere sia nella primavera che nell’autunno 2023 per scoprire le iconiche città che si affacciano sul Mediterraneo a bordo di Msc Orchestra in maggio e giugno e Msc Euribia e Msc Seaview in autunno. Anche la nuova ammiraglia Msc World Europa proporrà nell’aprile 2023 un breve tour di quattro notti che partirà da Genova e toccherà i porti di Barcellona e Marsiglia.

Nord America e Caraibi:

Msc Meraviglia da aprile 2023 navigherà tutto l’anno da New York offrendo una grande varietà di itinerari che andranno da sei a 11 notti di lunghezza, tra cui:

Itinerari caraibici di sette o otto notti, con scali a Nassau e Ocean Cay Msc Marine Reserve – la bellissima isola privata alle Bahamas
Itinerari alle Bermuda della durata di sei notti con tre giorni di attracco a King’s Wharf e diversi giorni di relax in mare
Itinerari del Nord di dieci o 11 notti, con scali a Boston, Massachusetts; Portland, Maine (Usa) e Charlottetown, Prince Edward Island; Halifax e Sydney, Nova Scotia; e Saint Johns, Newfoundland (Canada). Gli itinerari di 11 notti includono uno scalo aggiuntivo a Newport, Rhode Island (Usa)




Msc Seascape offrirà due diversi itinerari di sette notti da Miami, Florida:


Caraibi orientali: tappa a Ocean Cay Msc Marine Reserve e Nassau (Bahamas), San Juan (Porto Rico) e Puerto Plata (Repubblica Dominicana)
Caraibi occidentali: con scalo a Ocean Cay Msc Marine Reserve (Bahamas), Cozumel (Messico), George Town (Isole Cayman) e Ocho Rios (Giamaica)


Msc Seaside farà homeport a Orlando, Florida da Port Canaveral, il secondo homeport di Msc in Florida, offrendo:

Crociere di tre e quattro notti alla riserva marina Ocean Cay Msc (Bahamas)
Crociere di sette notti a Cozumel e Costa Maya (Messico), Belize, e Ocean Cay Msc Marine Reserve (Bahamas)


Msc Magnifica da Miami, Florida con nuove crociere brevi di tre o quattro notti il venerdì o il lunedì verso Key West in Florida, Nassau e Ocean Cay Msc Marine Reserve (Bahamas).


We  would love to  give thanks to the author of this article for this awesome  material



Msc apre le vendite per l’estate 2023: 22 navi per oltre 140 destinazioni

"
      ["date_timestamp"]=>
      int(1651198517)
    }
    [5]=>
    array(11) {
      ["title"]=>
      string(122) "El amor de Scarlett Johansson por la moda masculina inspiró un momento de alfombra roja a juego con Colin Jost – Inicio"
      ["link"]=>
      string(160) "https://coolnspicy.com/influential-people/el-amor-de-scarlett-johansson-por-la-moda-masculina-inspiro-un-momento-de-alfombra-roja-a-juego-con-colin-jost-inicio/"
      ["dc"]=>
      array(1) {
        ["creator"]=>
        string(11) "Harold Kent"
      }
      ["pubdate"]=>
      string(31) "Fri, 29 Apr 2022 02:01:21 +0000"
      ["category"]=>
      string(102) "Influential PeoplealfombraamorColinInicioinspiróJohanssonJostjuegomasculinamodamomentoporRojaScarlett"
      ["guid"]=>
      string(31) "https://coolnspicy.com/?p=24524"
      ["description"]=>
      string(821) "Scarlett Johansson es más que una actriz galardonada, una celebridad influyente y una mujer de negocios increíblemente talentosa: también es un ícono de la moda. Y resulta que muchos de los atuendos más famosos de la estrella de Marvel provienen de su amor por la moda masculina. Un momento de coincidencia en la alfombra roja ... Read more"
      ["content"]=>
      array(1) {
        ["encoded"]=>
        string(6283) "

Scarlett Johansson es más que una actriz galardonada, una celebridad influyente y una mujer de negocios increíblemente talentosa: también es un ícono de la moda. Y resulta que muchos de los atuendos más famosos de la estrella de Marvel provienen de su amor por la moda masculina.
Un momento de coincidencia en la alfombra roja con su esposo Colin Jost, en particular, se inspiró en gran medida en la moda masculina. De hecho, dice que siempre prefiere la moda masculina a la femenina. ¡Un momento del traje de poder incluso cubrió el crecimiento del bebé durante el embarazo de Johansson!

We  want to thank the author of this  post for this  incredible  web content



El amor de Scarlett Johansson por la moda masculina inspiró un momento de alfombra roja a juego con Colin Jost – Inicio

"
      }
      ["summary"]=>
      string(821) "Scarlett Johansson es más que una actriz galardonada, una celebridad influyente y una mujer de negocios increíblemente talentosa: también es un ícono de la moda. Y resulta que muchos de los atuendos más famosos de la estrella de Marvel provienen de su amor por la moda masculina. Un momento de coincidencia en la alfombra roja ... Read more"
      ["atom_content"]=>
      string(6283) "

Scarlett Johansson es más que una actriz galardonada, una celebridad influyente y una mujer de negocios increíblemente talentosa: también es un ícono de la moda. Y resulta que muchos de los atuendos más famosos de la estrella de Marvel provienen de su amor por la moda masculina.
Un momento de coincidencia en la alfombra roja con su esposo Colin Jost, en particular, se inspiró en gran medida en la moda masculina. De hecho, dice que siempre prefiere la moda masculina a la femenina. ¡Un momento del traje de poder incluso cubrió el crecimiento del bebé durante el embarazo de Johansson!

We  want to thank the author of this  post for this  incredible  web content



El amor de Scarlett Johansson por la moda masculina inspiró un momento de alfombra roja a juego con Colin Jost – Inicio

"
      ["date_timestamp"]=>
      int(1651197681)
    }
    [6]=>
    array(11) {
      ["title"]=>
      string(61) "Telefilm Canada unveils 15 Micro-Budget Production finallists"
      ["link"]=>
      string(112) "https://coolnspicy.com/movie-production-companies/telefilm-canada-unveils-15-micro-budget-production-finallists/"
      ["dc"]=>
      array(1) {
        ["creator"]=>
        string(12) "Sally Scully"
      }
      ["pubdate"]=>
      string(31) "Fri, 29 Apr 2022 01:53:56 +0000"
      ["category"]=>
      string(78) "Movie Production CompaniesCanadafinallistsMicroBudgetproductionTelefilmunveils"
      ["guid"]=>
      string(31) "https://coolnspicy.com/?p=24518"
      ["description"]=>
      string(679) "
 
 Telefilm Canada brass also said at a press conference at Toronto’s TIFF Bell Lightbox that the Talent Fund will subsidise the Program, while Technicolor is offering free digital distribution encoding services to finallists who want it. This is the third annual round of projects in the Micro-Budget Production Program, which supports emerging filmmakers ... Read more"
      ["content"]=>
      array(1) {
        ["encoded"]=>
        string(6363) "





		
	

Telefilm Canada brass also said at a press conference at Toronto’s TIFF Bell Lightbox that the Talent Fund will subsidise the Program, while Technicolor is offering free digital distribution encoding services to finallists who want it.
This is the third annual round of projects in the Micro-Budget Production Program, which supports emerging filmmakers seeking to produce their first feature-length films.
The scheme places emphasis on the use of digital platforms and developing their potential for distribution and audience engagement. Budgets for these projects must not exceed $250,000.
“In just three years, the Micro-Budget Production Program has already proven it can deliver,” said Telefilm Canada executive director Carolle Brabant (pictured). “It’s discovered inspiring new talent, several of whom have made it on the festival circuit.
“I’m thinking for example of Christian Sparkes, whose film Cast No Shadow won seven awards including Best Atlantic Film in the Atlantic Film Festival; Julie Lambert, with Un Film De Chasse De Filles, which won three awards at the Quebec City Film Festival; Kyle Thomas, with The Valley Below, which screened at the Toronto International Film Festival and the Vancouver International Film Festival; and Sonia Bonspille Boileau, whose film Le Dep will be featured at the Karlovy Vary International Film Festival.
“I’ve no doubt this third year’s finalists will also amaze us. Thank you to all our partners for their collaboration.”
The Talent Fund helps the film industry diversify its funding sources and promote its successes. Under the leadership of an advisory committee of eight business and community leaders, the Fund has raised more than C$15m to date from companies, foundations and individuals.
The money will be invested over a period of seven years. The Fund finances 60% of the Micro-Budget Production Program.
Hartley T Richardson, chair of the Talent Fund advisory committee, said: “I firmly believe that our industry’s successes strengthen Canada’s image on the international scene, while fostering job creation and contributing to our country’s financial success.
“Our efforts are important, because the Talent Fund allows Canadian filmmakers, and especially those of the next generation, to create more Canadian content and captivating stories. The Fund offers all Canadians a terrific opportunity to support and spotlight our homegrown talent.”
Jean Ducharme, vice-president of operations at Technicolor Montreal, added: “Technicolor is proud to be associated with Telefilm for its Micro-Budget Production Program. With this partnership, our goal is to support emerging filmmakers by putting our digital distribution expertise at their disposal.”
Telefilm’s promotional partner on the Program is imagineNATIVE Film + Media Arts Festival.
The 2015-2016 Micro-Budget Production Program Finallists:
A
Mitchell Stafiej (director, screenwriter), Daniel Dietzel (producer), Quebec, partner: Mel Hoppenheim School Of Cinema, Concordia University
Memory Is Our Homeland
Jonathan Durand (director, screenwriter, producer), Quebec, partner: Institut national de l’image et du son (INIS)
MIA
Jeremy Guenette (director, screenwriter, producer), Gabriel Lévesque (screenwriter, producer), Manitoba, partner: On Screen Manitoba
The Edict
Benjamin Ross Hayden (director, screenwriter, producer), Manitoba, partner: Adam Beach Film Institute
River Of Silence
Michael Auger (director, screenwriter, producer), Danette Chalifoux (screenwriter, producer), partner: Bosa Centre for Film & Animation, Capilano University, British Columbia
Cardinal
Greyson Moore (director, screenwriter), Aidan Shipley (director), Kristy Neville, Marianna Margaret, Justin Elchakieh (producers), Ontario, partner: Ryerson University
Feuilles Mortes, Thierry Bouffard, Steve Landry, Édouard Tremblay (directors, screenwriters), Jean-François Dugal, Éric Denis, Charles Gaudreau (producers), Quebec partner: Spirafilm
The Hanging Tree
Marshall Axani (director, screenwriter), Diana Donaldson (producer), British Columbia, partner: Bosa Centre for Film & Animation, Capilano University
The Land Of Rock And Gold
Janine Windolph, Daniel Redenbach (directors, screenwriters, producers), Saskatchewan, partner: University Of Regina
Play Your Gender
Stephanie Clattenburg (director, screenwriter), Sahar Yousefi (screenwriter, producer), Nova Scotia, partner: Atlantic Filmmakers Cooperative
The Space Between
Amy Jo Johnson (director, screenwriter), Jessica Adams (producer), Ontario, partner: Canadian Film Centre
The Stand Up Man
Aram Collier (director, screenwriter), Tony Lau (producer), Ontario, partner: York University
The Sun At Midnight
Kirsten Carthew (director, screenwriter), Amos Scott (producer), Northwest Territories, partner: Western Arctic Moving Pictures
The Train Whistle Does Not Blow
Ashley McKenzie (director, screenwriter), Nelson MacDonald (producer), Nova Scotia, partner: National Screen Institute (NSI)
Une Fille Comme Moi
Kristina Wagenbauer (director), Geneviève Simard (screenwriter), Quebec, partner: Institut national de l’image et du son (INIS)

We would like to  say thanks to the author of this  short article for this  outstanding  web content



Telefilm Canada unveils 15 Micro-Budget Production finallists

"
      }
      ["summary"]=>
      string(679) "
 
 Telefilm Canada brass also said at a press conference at Toronto’s TIFF Bell Lightbox that the Talent Fund will subsidise the Program, while Technicolor is offering free digital distribution encoding services to finallists who want it. This is the third annual round of projects in the Micro-Budget Production Program, which supports emerging filmmakers ... Read more"
      ["atom_content"]=>
      string(6363) "





		
	

Telefilm Canada brass also said at a press conference at Toronto’s TIFF Bell Lightbox that the Talent Fund will subsidise the Program, while Technicolor is offering free digital distribution encoding services to finallists who want it.
This is the third annual round of projects in the Micro-Budget Production Program, which supports emerging filmmakers seeking to produce their first feature-length films.
The scheme places emphasis on the use of digital platforms and developing their potential for distribution and audience engagement. Budgets for these projects must not exceed $250,000.
“In just three years, the Micro-Budget Production Program has already proven it can deliver,” said Telefilm Canada executive director Carolle Brabant (pictured). “It’s discovered inspiring new talent, several of whom have made it on the festival circuit.
“I’m thinking for example of Christian Sparkes, whose film Cast No Shadow won seven awards including Best Atlantic Film in the Atlantic Film Festival; Julie Lambert, with Un Film De Chasse De Filles, which won three awards at the Quebec City Film Festival; Kyle Thomas, with The Valley Below, which screened at the Toronto International Film Festival and the Vancouver International Film Festival; and Sonia Bonspille Boileau, whose film Le Dep will be featured at the Karlovy Vary International Film Festival.
“I’ve no doubt this third year’s finalists will also amaze us. Thank you to all our partners for their collaboration.”
The Talent Fund helps the film industry diversify its funding sources and promote its successes. Under the leadership of an advisory committee of eight business and community leaders, the Fund has raised more than C$15m to date from companies, foundations and individuals.
The money will be invested over a period of seven years. The Fund finances 60% of the Micro-Budget Production Program.
Hartley T Richardson, chair of the Talent Fund advisory committee, said: “I firmly believe that our industry’s successes strengthen Canada’s image on the international scene, while fostering job creation and contributing to our country’s financial success.
“Our efforts are important, because the Talent Fund allows Canadian filmmakers, and especially those of the next generation, to create more Canadian content and captivating stories. The Fund offers all Canadians a terrific opportunity to support and spotlight our homegrown talent.”
Jean Ducharme, vice-president of operations at Technicolor Montreal, added: “Technicolor is proud to be associated with Telefilm for its Micro-Budget Production Program. With this partnership, our goal is to support emerging filmmakers by putting our digital distribution expertise at their disposal.”
Telefilm’s promotional partner on the Program is imagineNATIVE Film + Media Arts Festival.
The 2015-2016 Micro-Budget Production Program Finallists:
A
Mitchell Stafiej (director, screenwriter), Daniel Dietzel (producer), Quebec, partner: Mel Hoppenheim School Of Cinema, Concordia University
Memory Is Our Homeland
Jonathan Durand (director, screenwriter, producer), Quebec, partner: Institut national de l’image et du son (INIS)
MIA
Jeremy Guenette (director, screenwriter, producer), Gabriel Lévesque (screenwriter, producer), Manitoba, partner: On Screen Manitoba
The Edict
Benjamin Ross Hayden (director, screenwriter, producer), Manitoba, partner: Adam Beach Film Institute
River Of Silence
Michael Auger (director, screenwriter, producer), Danette Chalifoux (screenwriter, producer), partner: Bosa Centre for Film & Animation, Capilano University, British Columbia
Cardinal
Greyson Moore (director, screenwriter), Aidan Shipley (director), Kristy Neville, Marianna Margaret, Justin Elchakieh (producers), Ontario, partner: Ryerson University
Feuilles Mortes, Thierry Bouffard, Steve Landry, Édouard Tremblay (directors, screenwriters), Jean-François Dugal, Éric Denis, Charles Gaudreau (producers), Quebec partner: Spirafilm
The Hanging Tree
Marshall Axani (director, screenwriter), Diana Donaldson (producer), British Columbia, partner: Bosa Centre for Film & Animation, Capilano University
The Land Of Rock And Gold
Janine Windolph, Daniel Redenbach (directors, screenwriters, producers), Saskatchewan, partner: University Of Regina
Play Your Gender
Stephanie Clattenburg (director, screenwriter), Sahar Yousefi (screenwriter, producer), Nova Scotia, partner: Atlantic Filmmakers Cooperative
The Space Between
Amy Jo Johnson (director, screenwriter), Jessica Adams (producer), Ontario, partner: Canadian Film Centre
The Stand Up Man
Aram Collier (director, screenwriter), Tony Lau (producer), Ontario, partner: York University
The Sun At Midnight
Kirsten Carthew (director, screenwriter), Amos Scott (producer), Northwest Territories, partner: Western Arctic Moving Pictures
The Train Whistle Does Not Blow
Ashley McKenzie (director, screenwriter), Nelson MacDonald (producer), Nova Scotia, partner: National Screen Institute (NSI)
Une Fille Comme Moi
Kristina Wagenbauer (director), Geneviève Simard (screenwriter), Quebec, partner: Institut national de l’image et du son (INIS)

We would like to  say thanks to the author of this  short article for this  outstanding  web content



Telefilm Canada unveils 15 Micro-Budget Production finallists

"
      ["date_timestamp"]=>
      int(1651197236)
    }
    [7]=>
    array(11) {
      ["title"]=>
      string(101) "Gene mutations that contribute to head and neck cancer also provide ‘precision’ treatment targets"
      ["link"]=>
      string(136) "https://coolnspicy.com/healthandscience/gene-mutations-that-contribute-to-head-and-neck-cancer-also-provide-precision-treatment-targets/"
      ["dc"]=>
      array(1) {
        ["creator"]=>
        string(12) "Tony Grantly"
      }
      ["pubdate"]=>
      string(31) "Fri, 29 Apr 2022 01:33:19 +0000"
      ["category"]=>
      string(83) "Health And SciencecancercontributegeneMutationsneckprecisionprovidetargetstreatment"
      ["guid"]=>
      string(31) "https://coolnspicy.com/?p=24513"
      ["description"]=>
      string(797) "Journal Reference: Hoi-Lam Ngan, Chun-Ho Law, Yannie Chung Yan Choi, Jenny Yu-Sum Chan, Vivian Wai Yan Lui. Precision drugging of the MAPK pathway in head and neck cancer. npj Genomic Medicine, 2022; 7 (1) DOI: 10.1038/s41525-022-00293-1 Keys to targeting that vulnerability include individualized genomic analysis to identify a patient’s specific mutation, and finding the drugs ... Read more"
      ["content"]=>
      array(1) {
        ["encoded"]=>
        string(11572) "

Journal Reference:

Hoi-Lam Ngan, Chun-Ho Law, Yannie Chung Yan Choi, Jenny Yu-Sum Chan, Vivian Wai Yan Lui. Precision drugging of the MAPK pathway in head and neck cancer. npj Genomic Medicine, 2022; 7 (1) DOI: 10.1038/s41525-022-00293-1


Keys to targeting that vulnerability include individualized genomic analysis to identify a patient’s specific mutation, and finding the drugs that directly target it, investigations that should be given more attention in cancer therapy development, they report in a review article in the journal NPJ Genomic Medicine.
The MAPK pathway is a “signaling hub” for cells important to the usual development of the head and neck region, and activating key pathway constituents, like the genes MAPK1 and HRAS, is known to drive the growth of a variety of cancers, says Dr. Vivian Wai Yan Lui, molecular pharmacologist and translational scientist at the Georgia Cancer Center and Medical College of Georgia and the paper’s corresponding author.
But the mutations in the genes in the MAPK pathway that enable tumor growth can also make it sensitive to drug therapy, says Lui. While a lot of discovery is still needed to find more mutations in the MAPK pathway and the drugs that target them, Lui says they are among the most logical treatment targets for this tough-to-treat cancer.
As she speaks, she is looking in her lab for drugs that kill head and neck primary tumors from patients, and at the genetics behind how they kill.
“It’s critical to the survival of the cancer,” says Lui, and every cancer type likely has one or more drug-sensitizing mutations that may vary in individuals depending on how they got cancer.
If these types of studies continue to find the methodology works, gene panels might need to be developed to expedite target discovery in this very heterogenous cancer, the scientists write.
More clinical trials around the globe at institutions like MCG and the Georgia Cancer Center are essential to identifying these specific mutations and drugs that target them in a precision manner, Lui notes.
Also, next on the horizon is combining this “precision medicine” approach with immunotherapy that better enables a patient’s immune system to also target the cancer, she says.
Lui’s interest in the MAPK pathway solidified almost a decade ago at the University of Pittsburgh where she did her postdoctoral studies and eventually joined the faculty. Her mentor was Dr. Jennifer R. Grandis (now at the University of California, San Francisco), who led the head and neck cancer program there. The patient in his 30s, a heavy smoker and drinker, had stage four head and neck squamous cell carcinoma that had metastasized to his lymph nodes. The patient went to Pittsburgh for removal of the lymph nodes and the primary tumor but was fortunate enough to be eligible for a “window of opportunity” trial there. Before starting any standard treatment, he received a trial drug for 13 days, in his case an epidermal growth factor receptor, or EGFR, blocker. The receptor is involved in cell growth, and is found on some normal cells, including in the head and neck area where there is a lot of natural cell turnover because of exposure to things like food and drink. However, in cancer cells, including head and neck cancer cells, EGFR is abundantly expressed for the rapid growth critical to a tumor’s spread and survival.
The patient was given the drug, erlotinib, which was not known to be particularly effective in these cancers but was being looked at to see if it would quieten signaling of this factor that was important to the cancer’s growth. When he went for surgery following the trial, the surgeon called to report there was no cancer on his tongue and studies of his 36 lymph nodes indicated they also now showed no evidence of cancer. The patient was still doing well by the time the Pittsburgh colleagues published the paper two years later in 2015 in JAMA Oncology.
His was rightly called an “exceptional response,” the first Lui and her colleagues had found in head and neck cancer, and she had to figure out the mutation the drug targeted to enable such a response. Exceptional responders are how the National Cancer Institute describes people who have more than a six-month response to a therapy when they are running out of treatment options.
An EGFR gene mutation was a logical choice for his mutation. Harvard investigators had previously found that in non-small cell lung cancer, EGFR activating mutations could activate tumor cell growth, which also made tumor cells “addicted” to the signal from the mutated EGFR. The drug erlotinib could break the addiction and inhibit cancer cell growth.
Lui didn’t find an EGFR mutation in this young man’s pretreatment biopsy but reasoned the mutation had to have something to do with the receptor’s signaling network. She was surprised — and the first — to find it was a MAPK1 gene mutation, MAPK1 p.E322K specifically, that could also be found in liver, breast and other cancers.
When they later engineered the mutation in head and neck cancer cells, the already aggressive cells grew even faster, Lui says of a mutation that can result from habits like heavy smoking and drinking. They would also find that the particular mutation was very common in the United States in patients with head and neck cancer, while there was a wider spectrum of mutations present in Asians with the cancer.
Erlotinib had actually failed in clinical trials because it wasn’t given to the right patients, which is what precision medicine is, Lui notes. In fact, laboratory studies had indicated that activation of MAPK1 confers resistance to erlotinib, she says, while this patient’s response clearly counters that. Follow up work by Grandis indicated that in patients actually, the higher the MAPK1 activation, the better the cancer responded to erlotinib.
To help move cancer treatment forward, Lui encourages physicians who come across these types of “exceptional responses” to report them, work with scientists to study them, then pursue clinical trials when appropriate.
For patients, her message is not to give up because with more high-level analysis of tumors, there might be a certain mutation that makes their cancer vulnerable to a specific medication, she says of these “gene-drug responses” that are the focal point of her translational work.
“There are secrets that make the cancer vulnerable,” Lui says. “When cancer cells have an important gene mutation that they are activating or that cancer cells are addicted to for survival, then when you hit that signaling pathway, the cancer cells will die or be really well controlled.”
Prior to the era of genomic medicine, when scientists began to identify and target a specific gene mutation, “non-precision” drug treatment of the MAPK pathway in head and neck cancers as well as other cancers were “futile,” and typically “failed miserably” in clinical trials, Lui and her colleagues write.
While the reasons may be uncertain, they likely include the wrong drug for that specific, problematic mutation, Lui says, as well as the fact that some MAPK pathway mutations are known to convey drug resistance.
Either way, there is a lot of work to do. Today there are just a handful of drugs that target specific, cancer-causing mutations in head and neck cancer but there aren’t effective precision drugs for about 80% of patients, Lui and her coauthors write.
But there is mounting evidence that targeting specific MAPK pathway mutations in the pathway like MAPK1, HRAS, KRAS and BRAF can be very effective for these patients.
As an example, the RAS inhibitor tipifarnib received Breakthrough Therapy Designation by the Food and Drug Administration in February 2021 for patients with a specific recurrent or metastatic HRAS-mutant head and neck squamous cell cancer. HRAS is involved in cell growth signaling.
Also, studies indicate that EGFR targeted therapy in metastatic non-small cell lung cancer, increases progression-free survival to a median of 18.9 months and median overall survival beyond three years and reduces death rates about 52%. In 2016 the Food and Drug Administration modified its approval of erlotinib to treat non-small cell lung cancer patients with the specific EGFR mutations. In 2020, the FDA approved erlotinib in combination with ramucirumab, a monoclonal antibody that binds to a receptor for vascular endothelial growth factor, or VEGF, which tumors use to grow the blood vessels they need to thrive, as a frontline treatment for these cancers. The FDA granted Breakthrough Therapy Designation to tipifarnib, an inhibitor of a protein which has the downstream effect of interfering in this case with mutations of the gene HRAS, which is also involved in cell division and in the MAPK pathway. There are now more than 1.5 million people with non-small cell lung cancer on precision medicine because of investigators who continued to examine the initial few responders, Lui says.
Lui is a native of Hong Kong, who was on the faculty of The Chinese University of Hong Kong before joining the MCG faculty in October 2021. In 2020 Lui and her colleagues reported that MAPK pathway mutations are a factor in about one-fifth of head and neck cancer patients and that “unexpectedly” these mutations are associated with longer patient survival than other causes like human papillomavirus.
Head and neck cancer is typically aggressive and often both the disease and its treatment are painful and disfiguring. It carries a higher risk of suicide than many other cancer types. The incidence of head and neck cancer is going up across the world, with causes including tobacco and/or alcohol use, air pollutants, cancer causing viruses like the sexually transmitted HPV, and Epstein-Barr virus, one of the most common viruses that is primarily spread by saliva and can cause problems like infectious mononucleosis. Other causes include poor dental hygiene and chewing betel nut, a stimulant which comes from the Areca palm plant, and is used as a recreational drug and as a still-unproven treatment for problems like schizophrenia and glaucoma. Chewing betel nut is a common cultural practice in South and Southeast Asia and the Asian Pacific. It’s often chewed with products like tobacco and has been associated with cancer and a host of other medical problems like a slow heart rate and stomach ulcers.
The carcinogens largely damage the lining of the head and neck region resulting in one or more mutations that can lead to cancer.

We  would love to  say thanks to the author of this article for this  remarkable  web content



Gene mutations that contribute to head and neck cancer also provide ‘precision’ treatment targets

"
      }
      ["summary"]=>
      string(797) "Journal Reference: Hoi-Lam Ngan, Chun-Ho Law, Yannie Chung Yan Choi, Jenny Yu-Sum Chan, Vivian Wai Yan Lui. Precision drugging of the MAPK pathway in head and neck cancer. npj Genomic Medicine, 2022; 7 (1) DOI: 10.1038/s41525-022-00293-1 Keys to targeting that vulnerability include individualized genomic analysis to identify a patient’s specific mutation, and finding the drugs ... Read more"
      ["atom_content"]=>
      string(11572) "

Journal Reference:

Hoi-Lam Ngan, Chun-Ho Law, Yannie Chung Yan Choi, Jenny Yu-Sum Chan, Vivian Wai Yan Lui. Precision drugging of the MAPK pathway in head and neck cancer. npj Genomic Medicine, 2022; 7 (1) DOI: 10.1038/s41525-022-00293-1


Keys to targeting that vulnerability include individualized genomic analysis to identify a patient’s specific mutation, and finding the drugs that directly target it, investigations that should be given more attention in cancer therapy development, they report in a review article in the journal NPJ Genomic Medicine.
The MAPK pathway is a “signaling hub” for cells important to the usual development of the head and neck region, and activating key pathway constituents, like the genes MAPK1 and HRAS, is known to drive the growth of a variety of cancers, says Dr. Vivian Wai Yan Lui, molecular pharmacologist and translational scientist at the Georgia Cancer Center and Medical College of Georgia and the paper’s corresponding author.
But the mutations in the genes in the MAPK pathway that enable tumor growth can also make it sensitive to drug therapy, says Lui. While a lot of discovery is still needed to find more mutations in the MAPK pathway and the drugs that target them, Lui says they are among the most logical treatment targets for this tough-to-treat cancer.
As she speaks, she is looking in her lab for drugs that kill head and neck primary tumors from patients, and at the genetics behind how they kill.
“It’s critical to the survival of the cancer,” says Lui, and every cancer type likely has one or more drug-sensitizing mutations that may vary in individuals depending on how they got cancer.
If these types of studies continue to find the methodology works, gene panels might need to be developed to expedite target discovery in this very heterogenous cancer, the scientists write.
More clinical trials around the globe at institutions like MCG and the Georgia Cancer Center are essential to identifying these specific mutations and drugs that target them in a precision manner, Lui notes.
Also, next on the horizon is combining this “precision medicine” approach with immunotherapy that better enables a patient’s immune system to also target the cancer, she says.
Lui’s interest in the MAPK pathway solidified almost a decade ago at the University of Pittsburgh where she did her postdoctoral studies and eventually joined the faculty. Her mentor was Dr. Jennifer R. Grandis (now at the University of California, San Francisco), who led the head and neck cancer program there. The patient in his 30s, a heavy smoker and drinker, had stage four head and neck squamous cell carcinoma that had metastasized to his lymph nodes. The patient went to Pittsburgh for removal of the lymph nodes and the primary tumor but was fortunate enough to be eligible for a “window of opportunity” trial there. Before starting any standard treatment, he received a trial drug for 13 days, in his case an epidermal growth factor receptor, or EGFR, blocker. The receptor is involved in cell growth, and is found on some normal cells, including in the head and neck area where there is a lot of natural cell turnover because of exposure to things like food and drink. However, in cancer cells, including head and neck cancer cells, EGFR is abundantly expressed for the rapid growth critical to a tumor’s spread and survival.
The patient was given the drug, erlotinib, which was not known to be particularly effective in these cancers but was being looked at to see if it would quieten signaling of this factor that was important to the cancer’s growth. When he went for surgery following the trial, the surgeon called to report there was no cancer on his tongue and studies of his 36 lymph nodes indicated they also now showed no evidence of cancer. The patient was still doing well by the time the Pittsburgh colleagues published the paper two years later in 2015 in JAMA Oncology.
His was rightly called an “exceptional response,” the first Lui and her colleagues had found in head and neck cancer, and she had to figure out the mutation the drug targeted to enable such a response. Exceptional responders are how the National Cancer Institute describes people who have more than a six-month response to a therapy when they are running out of treatment options.
An EGFR gene mutation was a logical choice for his mutation. Harvard investigators had previously found that in non-small cell lung cancer, EGFR activating mutations could activate tumor cell growth, which also made tumor cells “addicted” to the signal from the mutated EGFR. The drug erlotinib could break the addiction and inhibit cancer cell growth.
Lui didn’t find an EGFR mutation in this young man’s pretreatment biopsy but reasoned the mutation had to have something to do with the receptor’s signaling network. She was surprised — and the first — to find it was a MAPK1 gene mutation, MAPK1 p.E322K specifically, that could also be found in liver, breast and other cancers.
When they later engineered the mutation in head and neck cancer cells, the already aggressive cells grew even faster, Lui says of a mutation that can result from habits like heavy smoking and drinking. They would also find that the particular mutation was very common in the United States in patients with head and neck cancer, while there was a wider spectrum of mutations present in Asians with the cancer.
Erlotinib had actually failed in clinical trials because it wasn’t given to the right patients, which is what precision medicine is, Lui notes. In fact, laboratory studies had indicated that activation of MAPK1 confers resistance to erlotinib, she says, while this patient’s response clearly counters that. Follow up work by Grandis indicated that in patients actually, the higher the MAPK1 activation, the better the cancer responded to erlotinib.
To help move cancer treatment forward, Lui encourages physicians who come across these types of “exceptional responses” to report them, work with scientists to study them, then pursue clinical trials when appropriate.
For patients, her message is not to give up because with more high-level analysis of tumors, there might be a certain mutation that makes their cancer vulnerable to a specific medication, she says of these “gene-drug responses” that are the focal point of her translational work.
“There are secrets that make the cancer vulnerable,” Lui says. “When cancer cells have an important gene mutation that they are activating or that cancer cells are addicted to for survival, then when you hit that signaling pathway, the cancer cells will die or be really well controlled.”
Prior to the era of genomic medicine, when scientists began to identify and target a specific gene mutation, “non-precision” drug treatment of the MAPK pathway in head and neck cancers as well as other cancers were “futile,” and typically “failed miserably” in clinical trials, Lui and her colleagues write.
While the reasons may be uncertain, they likely include the wrong drug for that specific, problematic mutation, Lui says, as well as the fact that some MAPK pathway mutations are known to convey drug resistance.
Either way, there is a lot of work to do. Today there are just a handful of drugs that target specific, cancer-causing mutations in head and neck cancer but there aren’t effective precision drugs for about 80% of patients, Lui and her coauthors write.
But there is mounting evidence that targeting specific MAPK pathway mutations in the pathway like MAPK1, HRAS, KRAS and BRAF can be very effective for these patients.
As an example, the RAS inhibitor tipifarnib received Breakthrough Therapy Designation by the Food and Drug Administration in February 2021 for patients with a specific recurrent or metastatic HRAS-mutant head and neck squamous cell cancer. HRAS is involved in cell growth signaling.
Also, studies indicate that EGFR targeted therapy in metastatic non-small cell lung cancer, increases progression-free survival to a median of 18.9 months and median overall survival beyond three years and reduces death rates about 52%. In 2016 the Food and Drug Administration modified its approval of erlotinib to treat non-small cell lung cancer patients with the specific EGFR mutations. In 2020, the FDA approved erlotinib in combination with ramucirumab, a monoclonal antibody that binds to a receptor for vascular endothelial growth factor, or VEGF, which tumors use to grow the blood vessels they need to thrive, as a frontline treatment for these cancers. The FDA granted Breakthrough Therapy Designation to tipifarnib, an inhibitor of a protein which has the downstream effect of interfering in this case with mutations of the gene HRAS, which is also involved in cell division and in the MAPK pathway. There are now more than 1.5 million people with non-small cell lung cancer on precision medicine because of investigators who continued to examine the initial few responders, Lui says.
Lui is a native of Hong Kong, who was on the faculty of The Chinese University of Hong Kong before joining the MCG faculty in October 2021. In 2020 Lui and her colleagues reported that MAPK pathway mutations are a factor in about one-fifth of head and neck cancer patients and that “unexpectedly” these mutations are associated with longer patient survival than other causes like human papillomavirus.
Head and neck cancer is typically aggressive and often both the disease and its treatment are painful and disfiguring. It carries a higher risk of suicide than many other cancer types. The incidence of head and neck cancer is going up across the world, with causes including tobacco and/or alcohol use, air pollutants, cancer causing viruses like the sexually transmitted HPV, and Epstein-Barr virus, one of the most common viruses that is primarily spread by saliva and can cause problems like infectious mononucleosis. Other causes include poor dental hygiene and chewing betel nut, a stimulant which comes from the Areca palm plant, and is used as a recreational drug and as a still-unproven treatment for problems like schizophrenia and glaucoma. Chewing betel nut is a common cultural practice in South and Southeast Asia and the Asian Pacific. It’s often chewed with products like tobacco and has been associated with cancer and a host of other medical problems like a slow heart rate and stomach ulcers.
The carcinogens largely damage the lining of the head and neck region resulting in one or more mutations that can lead to cancer.

We  would love to  say thanks to the author of this article for this  remarkable  web content



Gene mutations that contribute to head and neck cancer also provide ‘precision’ treatment targets

"
      ["date_timestamp"]=>
      int(1651195999)
    }
    [8]=>
    array(11) {
      ["title"]=>
      string(141) "Jeff Goldblum Comparte Pensamientos Después De Ver Jurassic World: Dominion (y Ya Tiene Planes De Volver) – Noticias Del Mundo En Español"
      ["link"]=>
      string(166) "https://coolnspicy.com/celebrity/jeff-goldblum-comparte-pensamientos-despues-de-ver-jurassic-world-dominion-y-ya-tiene-planes-de-volver-noticias-del-mundo-en-espanol/"
      ["dc"]=>
      array(1) {
        ["creator"]=>
        string(12) "Sally Scully"
      }
      ["pubdate"]=>
      string(31) "Fri, 29 Apr 2022 00:57:46 +0000"
      ["category"]=>
      string(109) "CelebritycompartedeldespuésDominionEspañolGoldblumJeffJurassicmundonoticiasPensamientosPlanestienevervolver"
      ["guid"]=>
      string(31) "https://coolnspicy.com/?p=24508"
      ["description"]=>
      string(854) "Mundo Jurásico: Dominio es sin duda uno de los lanzamientos más esperados de este año. La tercera película en el Mundo franquicia y sexta película de franquicia en general se dirige a la calendario de cine 2022 el 10 de junio. Todavía faltan varias semanas, pero resulta que el elenco ya vio la película completa, ... Read more"
      ["content"]=>
      array(1) {
        ["encoded"]=>
        string(4454) "

Mundo Jurásico: Dominio es sin duda uno de los lanzamientos más esperados de este año. La tercera película en el Mundo franquicia y sexta película de franquicia en general se dirige a la calendario de cine 2022 el 10 de junio. Todavía faltan varias semanas, pero resulta que el elenco ya vio la película completa, y Jeff Goldblum y Bryce Dallas Howard aparecieron en CinemaCon este año para hablar sobre su «infinita gratitud» por la franquicia y compartir su primeras tomas de la película. Ah, y el estreno de la nueva película también será un momento dulce para la familia de Jeff Goldblum.
Antes de compartir algunas imágenes nuevas, Jeff Goldblum y Bryce Dallas Howard hablaron un poco sobre sus experiencias en la icónica franquicia. Para Goldblum, ir al cine siempre ha sido la experiencia más «romántica» y «mágica» para él y parece genuinamente entusiasmado con lo que Dominio está llevando a la gran pantalla. 

We  would love to  say thanks to the author of this  write-up for this  amazing  material



Jeff Goldblum Comparte Pensamientos Después De Ver Jurassic World: Dominion (y Ya Tiene Planes De Volver) – Noticias Del Mundo En Español

"
      }
      ["summary"]=>
      string(854) "Mundo Jurásico: Dominio es sin duda uno de los lanzamientos más esperados de este año. La tercera película en el Mundo franquicia y sexta película de franquicia en general se dirige a la calendario de cine 2022 el 10 de junio. Todavía faltan varias semanas, pero resulta que el elenco ya vio la película completa, ... Read more"
      ["atom_content"]=>
      string(4454) "

Mundo Jurásico: Dominio es sin duda uno de los lanzamientos más esperados de este año. La tercera película en el Mundo franquicia y sexta película de franquicia en general se dirige a la calendario de cine 2022 el 10 de junio. Todavía faltan varias semanas, pero resulta que el elenco ya vio la película completa, y Jeff Goldblum y Bryce Dallas Howard aparecieron en CinemaCon este año para hablar sobre su «infinita gratitud» por la franquicia y compartir su primeras tomas de la película. Ah, y el estreno de la nueva película también será un momento dulce para la familia de Jeff Goldblum.
Antes de compartir algunas imágenes nuevas, Jeff Goldblum y Bryce Dallas Howard hablaron un poco sobre sus experiencias en la icónica franquicia. Para Goldblum, ir al cine siempre ha sido la experiencia más «romántica» y «mágica» para él y parece genuinamente entusiasmado con lo que Dominio está llevando a la gran pantalla. 

We  would love to  say thanks to the author of this  write-up for this  amazing  material



Jeff Goldblum Comparte Pensamientos Después De Ver Jurassic World: Dominion (y Ya Tiene Planes De Volver) – Noticias Del Mundo En Español

"
      ["date_timestamp"]=>
      int(1651193866)
    }
    [9]=>
    array(11) {
      ["title"]=>
      string(42) "Unravelling the origins of the human spine"
      ["link"]=>
      string(83) "https://coolnspicy.com/healthandscience/unravelling-the-origins-of-the-human-spine/"
      ["dc"]=>
      array(1) {
        ["creator"]=>
        string(12) "Tony Grantly"
      }
      ["pubdate"]=>
      string(31) "Fri, 29 Apr 2022 00:16:18 +0000"
      ["category"]=>
      string(46) "Health And ScienceHumanoriginsspineUnravelling"
      ["guid"]=>
      string(31) "https://coolnspicy.com/?p=24503"
      ["description"]=>
      string(658) "Journal Reference: Marina Sanaki-Matsumiya, Mitsuhiro Matsuda, Nicola Gritti, Fumio Nakaki, James Sharpe, Vikas Trivedi, Miki Ebisuya. Periodic formation of epithelial somites from human pluripotent stem cells. Nature Communications, 2022; 13 (1) DOI: 10.1038/s41467-022-29967-1 The spinal column consists of 33 vertebrae, which form pairs of precursor structures called somites. Somites give rise to not only our ... Read more"
      ["content"]=>
      array(1) {
        ["encoded"]=>
        string(4306) "

Journal Reference:

Marina Sanaki-Matsumiya, Mitsuhiro Matsuda, Nicola Gritti, Fumio Nakaki, James Sharpe, Vikas Trivedi, Miki Ebisuya. Periodic formation of epithelial somites from human pluripotent stem cells. Nature Communications, 2022; 13 (1) DOI: 10.1038/s41467-022-29967-1


The spinal column consists of 33 vertebrae, which form pairs of precursor structures called somites. Somites give rise to not only our vertebrae, but also our ribs and skeletal muscles. To ensure that these structures are formed correctly, somite development is tightly regulated, and each pair of somites arises at a particular sequential time point in development. This process is controlled by the segmentation clock, which is a group of genes that creates oscillatory waves, every wave giving rise to a new pair of somites.
“For the first time, we have been able to create periodic pairs of human mature somites linked to the segmentation clock in the lab,” said Marina Sanaki-Matsumiya, first author of the study published in Nature Communications. Using this approach, the researchers developed a 3D in vitro model of human somite formation, also known as ‘somitogenesis’.
Creating a robust somitogenesis process
The team cultured human induced pluripotent stem cells (hiPSC) in the presence of a cocktail of signalling molecules that induce cell differentiation. Three days later, the cells started to elongate and create anterior (top) and posterior (bottom) axes. At that point, the scientists added Matrigel to the culture mix. Matrigel is what some scientists call the magic powder: a protein mixture that is critical to many developmental processes. This process eventually led to the formation of somitoids — in vitro equivalents of human somite precursor structures.
To test whether the segmentation clock regulates somitogenesis in these somitoids, the researchers monitored the expression patterns of HES7, the core gene involved in the process. They found clear evidence of oscillations, especially when somitogenesis was about to start. The somites that formed also had clear markers of epithelization — an important step in their maturation.
Somite size matters
The Ebisuya group studies how and why we humans are different from other species when it comes to embryonic development. One of the model systems they use to understand interspecies differences is the segmentation clock. In 2020, the group uncovered that the oscillation period of the human segmentation clock is longer than the mouse segmentation clock.
The current study also shows a link between the size of somites and the segmentation clock. “The somites that were generated had a constant size, independently of the number of cells used for the initial somitoid. The somite size did not increase even if the initial cell number did.” explained Sanaki-Matsumiya. “This suggests that the somites have a preferred species-specific size, which might be determined by local cell-cell interactions, the segmentation clock, or other mechanisms.”
To study this further, Miki Ebisuya and her group are now planning to grow somitoids of different species and compare them. The researchers are already working on several mammalian species, including rabbits, cattle, and rhinoceroses, setting up a ‘stem cell zoo’ in the lab.
“Our next project will focus on creating somitoids from different species, measure their cell proliferation and cell migration speed to establish what and how somitogenesis is different among species,” said Ebisuya.

We  would love to thank the author of this  write-up for this  amazing content



Unravelling the origins of the human spine

"
      }
      ["summary"]=>
      string(658) "Journal Reference: Marina Sanaki-Matsumiya, Mitsuhiro Matsuda, Nicola Gritti, Fumio Nakaki, James Sharpe, Vikas Trivedi, Miki Ebisuya. Periodic formation of epithelial somites from human pluripotent stem cells. Nature Communications, 2022; 13 (1) DOI: 10.1038/s41467-022-29967-1 The spinal column consists of 33 vertebrae, which form pairs of precursor structures called somites. Somites give rise to not only our ... Read more"
      ["atom_content"]=>
      string(4306) "

Journal Reference:

Marina Sanaki-Matsumiya, Mitsuhiro Matsuda, Nicola Gritti, Fumio Nakaki, James Sharpe, Vikas Trivedi, Miki Ebisuya. Periodic formation of epithelial somites from human pluripotent stem cells. Nature Communications, 2022; 13 (1) DOI: 10.1038/s41467-022-29967-1


The spinal column consists of 33 vertebrae, which form pairs of precursor structures called somites. Somites give rise to not only our vertebrae, but also our ribs and skeletal muscles. To ensure that these structures are formed correctly, somite development is tightly regulated, and each pair of somites arises at a particular sequential time point in development. This process is controlled by the segmentation clock, which is a group of genes that creates oscillatory waves, every wave giving rise to a new pair of somites.
“For the first time, we have been able to create periodic pairs of human mature somites linked to the segmentation clock in the lab,” said Marina Sanaki-Matsumiya, first author of the study published in Nature Communications. Using this approach, the researchers developed a 3D in vitro model of human somite formation, also known as ‘somitogenesis’.
Creating a robust somitogenesis process
The team cultured human induced pluripotent stem cells (hiPSC) in the presence of a cocktail of signalling molecules that induce cell differentiation. Three days later, the cells started to elongate and create anterior (top) and posterior (bottom) axes. At that point, the scientists added Matrigel to the culture mix. Matrigel is what some scientists call the magic powder: a protein mixture that is critical to many developmental processes. This process eventually led to the formation of somitoids — in vitro equivalents of human somite precursor structures.
To test whether the segmentation clock regulates somitogenesis in these somitoids, the researchers monitored the expression patterns of HES7, the core gene involved in the process. They found clear evidence of oscillations, especially when somitogenesis was about to start. The somites that formed also had clear markers of epithelization — an important step in their maturation.
Somite size matters
The Ebisuya group studies how and why we humans are different from other species when it comes to embryonic development. One of the model systems they use to understand interspecies differences is the segmentation clock. In 2020, the group uncovered that the oscillation period of the human segmentation clock is longer than the mouse segmentation clock.
The current study also shows a link between the size of somites and the segmentation clock. “The somites that were generated had a constant size, independently of the number of cells used for the initial somitoid. The somite size did not increase even if the initial cell number did.” explained Sanaki-Matsumiya. “This suggests that the somites have a preferred species-specific size, which might be determined by local cell-cell interactions, the segmentation clock, or other mechanisms.”
To study this further, Miki Ebisuya and her group are now planning to grow somitoids of different species and compare them. The researchers are already working on several mammalian species, including rabbits, cattle, and rhinoceroses, setting up a ‘stem cell zoo’ in the lab.
“Our next project will focus on creating somitoids from different species, measure their cell proliferation and cell migration speed to establish what and how somitogenesis is different among species,” said Ebisuya.

We  would love to thank the author of this  write-up for this  amazing content



Unravelling the origins of the human spine

"
      ["date_timestamp"]=>
      int(1651191378)
    }
  }
  ["channel"]=>
  array(7) {
    ["title"]=>
    string(12) "Cool N Spicy"
    ["link"]=>
    string(22) "https://coolnspicy.com"
    ["lastbuilddate"]=>
    string(31) "Fri, 29 Apr 2022 04:28:44 +0000"
    ["language"]=>
    string(5) "en-US"
    ["sy"]=>
    array(2) {
      ["updateperiod"]=>
      string(9) "
	hourly	"
      ["updatefrequency"]=>
      string(4) "
	1	"
    }
    ["generator"]=>
    string(28) "https://wordpress.org/?v=6.0"
    ["tagline"]=>
    NULL
  }
  ["textinput"]=>
  array(0) {
  }
  ["image"]=>
  array(0) {
  }
  ["feed_type"]=>
  string(3) "RSS"
  ["feed_version"]=>
  string(3) "2.0"
  ["encoding"]=>
  string(5) "UTF-8"
  ["_source_encoding"]=>
  string(0) ""
  ["ERROR"]=>
  string(0) ""
  ["WARNING"]=>
  string(0) ""
  ["_CONTENT_CONSTRUCTS"]=>
  array(6) {
    [0]=>
    string(7) "content"
    [1]=>
    string(7) "summary"
    [2]=>
    string(4) "info"
    [3]=>
    string(5) "title"
    [4]=>
    string(7) "tagline"
    [5]=>
    string(9) "copyright"
  }
  ["_KNOWN_ENCODINGS"]=>
  array(3) {
    [0]=>
    string(5) "UTF-8"
    [1]=>
    string(8) "US-ASCII"
    [2]=>
    string(10) "ISO-8859-1"
  }
  ["stack"]=>
  array(0) {
  }
  ["inchannel"]=>
  bool(false)
  ["initem"]=>
  bool(false)
  ["incontent"]=>
  bool(false)
  ["intextinput"]=>
  bool(false)
  ["inimage"]=>
  bool(false)
  ["current_namespace"]=>
  bool(false)
  ["last_modified"]=>
  string(31) "Fri, 29 Apr 2022 04:28:44 GMT
"
  ["etag"]=>
  string(43) "W/"5e5ff46498c4f7000d8892ebdbb0429d-gzip"
"
}